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  ABSTRACT 
The potential of human embryonic stem cells (hESCs) to differentiate into insulin 
producing β cells offers great hope for cell-based therapy for diabetes treatment. However, in 
vitro pancreatic differentiation of hESCs remains challenging. In the past decade, most protocols 
for differentiating pancreatic cells have been focused on the use of signaling molecule cocktails 
on 2D substrates. Studies on embryonic development biology strongly suggest that extracellular 
matrix (ECM) plays a critical role on hESCs behavior. In this work, we first established a 3D 
collagen scaffold culture system for hESCs differentiating into definitive endoderm (DE), which 
is the first and most important step for coaxing hESCs into transplantable β cells. Collagen 
scaffold have shown to promote the attachment, proliferation and DE differentiation of hESCs in 
3D microenvironment. Furthermore, we optimized the 3D scaffold compositions by integrating 
various ECM proteins into collagen scaffold. Our data showed that compared to collagen with 
single ECM protein, collagen combined with fibronectin, laminin, and vitronectin can greatly 
enhance DE differentiation generating up to 93% SOX17 positive DE population. Finally, we 
demonstrated that mature insulin-producing cells can be achieved by differentiating hESCs in 3D 
biomimic scaffold made of collagen and Matrigel, combined with a modified step-wise protocol. 
More mature insulin-producing cells were generated with our 3D scaffold compared to 
traditional 2D culture. The 3D differentiated pancreatic endocrine cells were assembled into 
tissue-like structure and displayed greater similarities in phenotype and gene expression profile 
to adult human islets. These hESC-induced pancreatic cells comprised 20% insulin positive cells 
in 3D culture and can response to high glucose and release four-fold insulin as compared to 2D 
culture. Insulin-secreting granules were also observed, which confirmed the generation of 
insulin-producing cells in 3D scaffold. 
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CHAPTER 1 
INTRODUCTION 
1.1. Stem cells 
Stem cells are type of cells that have the capability of self-renewal and differentiation [1]. 
More explicitly, stem cells can divide and generate daughter cells that are identical to their 
mother cells (self-renewal), as well as give rise to other daughter cells that produce differentiated 
descendants with more lineage-restricted potential (differentiation). There are three basic types 
of stem cells: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult 
stem cells (ASCs).  Tremendous attentions and interests have been directed toward research in 
the area of stem cells, owing to their unique properties. By understanding stem cells, it will offer 
insight into the biology of cells as well as a path for cell replacement and transplantation therapy.  
 
1.1.1 Embryonic stem cells 
Shortly after fertilization, mammalian embryos undergo a series of divisions to form the 
morula, a solid ball-like aggregate of totipotent cells which, if isolated, have the ability to 
develop into a complete organism [2, 3]. Further cell divisions convert morula into a blastocyst, a 
cystlike structure with an inner cavity surrounded by cells. The cells of outer layer of blastocyst 
differentiate into the trophoblast that eventually become the placenta and sustains nutrient supply 
to the embryo. In contrast, the cells of inner layer, called inner cell mass (ICM), which remain 
pluripotent and are capable of extensive, perhaps unlimited, self-renewal, ultimately develop into 
the fetus. In 1981, similar work by Martin Evans and Matthew Kaufman as well as Gail Martin 
showed that mouse embryos can be cultured in vitro and ICM cells can be isolated from these 
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embryos and cultured outside the body without losing their pluripotency [4, 5]. These cultured 
cells were then named as embryonic stem cells (ESCs). In 1998, Thomson et al. developed a 
technique to isolate and grow human embryonic stem cells (hESCs) in vitro [6]. The isolation of 
stable hESCs from donated, otherwise discarded, human blastocysts, therefore, creates a 
potentially unlimited source of any human cell types, and thus sets the stage for cell replacement 
therapy. hESCs hold enormous promising for understanding development of many diseases as 
well as for treating devastating and currently incurable disorders such as spinal cord injury, 
neurological disease, blindness and type 1 diabetes.  
 
1.1.2 Adult stem cells 
Adult stem cells, also called somatic stem cells, are undifferentiated cells that reside in 
developed tissues of juvenile as well as adult bodies. Adult stem cells have the ability of 
indefinite self-renewal, so they can divide regularly to replenish dying cells and to regenerate 
damaged tissues. Unlike ES cells, the differentiation ability of adult stem cells are more lineage-
restricted, i.e. they can only generate progeny of several distinct cell types, which related to their 
tissue origin (multipotency), as opposed to the pluripotency of ES cells. Adult stem cells have 
been found in blood, brain, muscle, skin, bone etc. 
Adult stem cells have been successfully used for disease treatment for many years. Bone 
marrow transplantation has been approved for patients with inherited blood disorder, blood 
cancers such as lymphoma and leukemia, or who are undergoing chemotherapy or radiotherapy. 
Autologous hematopoietic stem cells (HSCs) have been successfully applied to treat spinal cord 
injury [7], liver cirrhosis [8] and peripheral vascular ischemia [9]. Mesenchymal stem cells 
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(MSCs) have been used in the treatment of patients with osteogenesis imperfect, infarcted 
myocardium, or joint disease [10-12]. Neural stem cells (NSCs) can differentiate to neurons, 
astrocytes and oligodentrocytes and have been used in a number of clinical trials for 
neurometabolic and neurodegenerative diseases like Parkinson’s disease [13, 14].  Although the 
use of adult stem cells in research and therapy is not considered to be controversial, these cells 
may not be as versatile and durable as ESCs. First, adult stem cells are rare in adult tissues and 
are difficult to isolate and maintain in vitro. Also, their proliferation potential is not comparable 
to ESCs, so harvesting and culturing them up to scale for clinic purpose remains challenge.  
Second, adult stem cells are not able to produce all cell types, limiting their use in disease 
treatment. Furthermore, they are more likely to contain abnormalities due to environmental 
hazards, such as toxins, or from cell replication error.  
 
1.1.3 Induced pluripotent stem cells (iPSCs) 
In 2006, Dr. Yamanaka made a breakthrough discovery that through retroviral 
transfection of a defined set of transcription factors (Oct3/4, Sox2, c-Myc, and Klf4), adult 
somatic cells can be genetically reprogrammed into cells which have pluripotent capability and 
behave equivalent to ESCs, termed as induced pluripotent stem cells (iPSCs) [15]. This 
discovery has made Yamanaka won the Noble Prize in Physiology or Medicine in 2012. To date, 
iPSCs have been successfully generated from multiple types of human somatic cells, including 
fibroblasts [16-18], blood cells [19], neural progenitors [20], and terminally differentiated mature 
B lymphocytes [21]. Also, as alternatives to potentially harmful retroviruses strategy, multiple 
approaches have been proposed to generate iPSCs, including virus-free transposonsystem [22], 
mimicking transcription factors with small-molecule compounds [23-25], drug-inducible systems 
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[26, 27], recombinant proteins [28, 29]and microRNAs [30, 31]. The high degree of similarity 
between iPSCs and ESCs has been confirmed on many levels, such as the expression of certain 
stem cell genes and proteins, in vitro differentiation analysis, teratoma formation [15, 16, 18], 
epigenetic studies [32], and tetraploid complementation [33, 34]. The development of iPSCs 
allows researchers to obtain patient-specific iPSCs that are theoretically tolerant to immune 
rejection. Thus, the development of iPSC technology has provided a powerful tool for 
biomedical research and widened the era of hope for patient-specific cell therapy, drug discovery, 
and disease modeling.  
However, the potential clinical application of iPSCs remains some limitations. First, the 
use of viruses for inducing iPSCs could potentially introduce cancers, which is considered a 
major obstacle to stem cell based regenerative medicine. Furthermore, although many 
similarities between ESCs and iPSCs, several studies have shown that these two pluripotent cell 
types display significant differences. A study of gene expression profile of mouse and human 
ESCs and iPSCs revealed that a recurrent gene expression signature appeared in iPSCs 
regardless of their origin or the method by which they were generated [35]. Also, reprogrammed 
iPSCs retained an epigenetic memory from their parental cells of origin, which directed iPSCs 
favor their differentiation along lineages related to the donor cells, while restricting alternative 
cell fates [36].  Meissen, J. K. et al. demonstrated that iPSCs showed metabolomic differences to 
ESCs, specifically for amino acids metabolism [37]. Also, a recent study reported that teratomas 
formed by iPSCs were mostly immune-rejected by recipients, which challenged the assumption 
of immunogenicity of iPSCs [38].  In addition, some studies showed iPSCs possess some 
somatic coding mutations of currently unknown functions [39-41]. 
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1. 2. Current and future therapies for diabetes mellitus  
 Insulin-secreting pancreatic β-cells are important for regulating mammalian metabolism. 
The deficiency of β-cell functions leads to diabetes, making patients suffer from hyperglycemia 
and mainly dependent on exogenously supply of insulin. Generating new functional β-cells 
would provide unprecedented opportunities for diabetes treatment. Based on the progressed 
understanding on β-cell development and the discovery of pluripotent stem cells, tremendous 
progress has been made to generate new pancreatic β-cells, including discovering and improving 
conditions that promote β-cell replication in vivo and in vitro, differentiating pluripotent stem 
cells into insulin-secreting β-cells, or converting terminally differentiated cell types into β-cells. 
Here, we summarized existing technologies that have been developed for generating 
physiological functioning β-cells that might be potentially used for cell transplantation for 
diabetes treatment. 
 
1.2.1. Diabetes mellitus 
 Diabetes mellitus is a leading metabolic disease characterized by hyperglycemia. Glucose 
level in blood is basically balanced by two types of cells, pancreatic β-cells and α-cells, which 
reside in pancreatic islets of Langerhans. Explicitly, increased glucose level stimulates insulin 
secretion by pancreatic β-cells.  Tissues such as liver and muscle will sense the signal of insulin 
and take up glucose from the blood. In contrast, when glucose level drops, α-cells secret 
glucagon and trigger the liver and muscles to produce glucose from stored glycogen. According 
to the statistics of the 2011 National Diabetes Fact Sheet from American Diabetes Association 
(ADA) (http://www.diabetes.org), 25.8 million children and adults have diabetes in the United 
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States alone, which is 8.3% of the population. Also, the total cost of diagnosed diabetes was 
$245 billion in the United States in 2012.  Worldwide, the prevalence of all diabetes types is 
increasing, and the total number of diabetes patients is estimated up to 366 million by 2030 
[42].Therefore, diabetes has become a growing global health problem with a striking impact on  
health, society and economy.  
 Diabetes is clinically classified into two major types: Type I or insulin-dependent 
diabetes (T1DM), which results from destruction of insulin-secreting β cells in the pancreatic 
islets of Langerhans by T cell-mediated autoimmune [43],  and Type II diabetes (T2DM) or non-
insulin-dependent diabetes, which develops when the body does not produce enough insulin or is 
not able to use it effectively, called  insulin resistance, which is often associated with obesity, 
age and genetic component [44]. Insulin resistant in peripheral tissues such as fat and muscle 
causes high demand on β-cells and leads to β-cell malfunction, de-differentiation and death [44]. 
A decrease in β cell mass of up to 60% has been reported in T2DM [45].  
 Since the successful isolation of biologically active insulin in the early 1920s, exogenous 
insulin injection combined with blood glucose monitoring and lifestyle adaption has remained 
the main treatment for diabetes. Although exogenous supply of insulin have greatly improved the 
lives of diabetic patients, the method is inaccurate and was not fully capable of mimicking the 
tight control of endogenously produced insulin release from pancreatic β-cells, thus cannot 
completely control the minutes-to-minutes fluctuations in systemic blood glucose. Poorly 
managed diabetes can lead to secondary complications including infections, cardiovascular 
disease, renal disease, autonomic and peripheral neuropathy, as well as visual impairment which 
can progress to blindness [46]. Therefore, in order to prevent these complications and improve 
patients' life quality, more precise glycemic control is necessary. The ultimate goal of diabetes 
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therapy is to restore patients' physiological insulin-secretion capability through β-cell 
transplantation or regeneration. 
 
1.2.2. Islet transplantation  
 Replenishing the functional β-cell mass is a commonly accepted strategy for diabetes 
treatment. The Edmonton Protocol first described an effective cell replacement therapy for 
T1DM [47]. Cadaveric donor islets were isolated and infused into the liver of diabetic patients 
via the portal vein, in conjunction with immunosuppressive regimen. The clinical outcomes of 
islet transplantation were very encouraging. The five year follow-up report from Shapiro and his 
colleagues reported that about 10% of the 65 patients enrolled in the Edmonton Center study 
remained insulin independence for 5 years after islet transplantation [48, 49]. The remaining 
patients, although not free from insulin replacement therapy, were protected from severe 
hypoglycemic episodes and diabetes-related complications. In recent data of 2010 annual report, 
the Collaborative Islet Transplantation Registry (http://www.citregistry.ory) reported that about 
25% of the 481 patients who received islet transplantation from 1999-2009 achieved insulin 
independence for 3 years. 
 The Edmonton protocol presents great potential as a treatment and cure for diabetes; 
however, its use has been limited by the scarcity of organs from cadaveric donors. Keymeulen et 
al. showed that the initial beta cell mass transplanted should be at least 2 × 106 cells/kg body 
weight in order to achieve a functioning graft and to achieve a reproducible metabolic control 
[50]; thus, the treating of one diabetic patient with this approach requires more than one donor 
for cell transplantation. Additionally, as islets are currently derived from cadavers, the host-graft 
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immune rejection is a significant limitation to transplantation therapy. Therefore, strategies to 
promote either the expansion of existing β-cells within the body or the supply of novel sources of 
clinically relevant β cell alternatives, which are reliable and reproducible, are currently debated 
as future treatment options.    
 
1.2.3. In vivo regeneration of pancreatic β-cells  
 Inadequate β-cell mass is common to both type 1 and type 2 diabetes (T1DM, T2DM). 
Recent studies using genetic lineage tracing or other cell labeling methods have shown that the 
growth and regeneration of adult β-cells do not involve specialized progenitors or non-β-cells 
[51-53]. In contrast, the postnatal β-cell mass are predominantly maintained via self-replication 
of pre-excising β-cells rather than stem cell differentiation. In Dor et al.'s study, they labeled 
pancreatic β-cells with human alkaline phosphatase by Cre-loxP-based conditional 
recombination in adult pancreas, and chased the face of pre-existing β-cells. The results showed 
that the labeling frequency of the β-cells remained unchanged, indicating that the new β-cells 
were generated primarily from pre-existing β-cells, rather than pluripotent stem cells, during 
adult life and after pancreatectomy in mice [51].  
 Normally, pancreatic size appears to be limited by the size of initial progenitor cell pool 
that is set aside in the developing pancreatic bud during embryogenesis [54]. Human adult 
pancreatic β-cells are known that they are highly specialized and have a low turnover rate due to 
tight cell cycle [55-57]. However, β-cell mass is dynamic and it undergoes significant changes 
under certain circumstances, including neonate, pregnancy and obesity. The pancreatic fractional 
area was increased by 1.4-fold to match dynamic physiological demands [58]. There is evidence 
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that circulating maternal hormones in the blood stream such as prolactin, placental lactogen can 
directly regulate β-cell proliferation in pregnancy through the intracellular factor menin [59-61]. 
Conversely, the turnover rate of β-cells slows down with aging [62].  Kassem et al. found that 
the rate of β-cell replication progressively decreased from 3% among fetal β-cells to less than 0.5% 
by 6 months of age [55].The mechanism of  these changes are unknown. At molecular level, 
there is evidence that cyclin-dependent kinase 4 (cdk4)-cyclin D complex is required for β-cell 
replication during neonatal and adult growth [63, 64]. In cyclin D-/- mice, pancreatic islets were 
dramatically smaller and β-cell mass was reduced 4-fold in comparison to wild-type mice. Thus, 
cycin D plays a key role in β-cell replication, which might be the primary mechanism underlying 
the maintenance of postnatal β-cell mass. Furthermore, a recent study showed that EGF-receptor 
signaling is essential in β-cell mass expansion in mice during high-fat diet and pregnancy [65]. 
These discoveries may provide a target for development of therapeutic strategies to induce the 
expansion of β-cells. 
 Most diabetic patients, even those with long-standing T1D, have a small number of β-
cells that continually replicate and undergo destruction, thus giving a hope that diabetes may be 
cured by preventing autoreactive β-cell destruction, and/or by supporting replication of the 
surviving β-cells [66]. Therefore, screening for factors that increase β-cell replication in vivo 
may have direct therapeutic benefits to diabetic patients. In vitro studies have shown that 
nicotinamide, an inhibitor of poly (adenosine diphosphate-ribose) synthethase/ polymerase, has 
the ability to induce proliferation and differentiation of pancreatic endocrine cells [67, 68]. 
Betacellulin, a growth factor of epidermal growth factor (EGF) family, has shown to promote 
neogenesis of β-cells and ameliorate glucose tolerance in mice [69] and promote proliferation of 
β-cells in 90% pancreatectomized rats [70]. Exendin-4, an analog of GLP-1, has shown to 
 10 
 
stimulate both β-cell proliferation and neogenesis in rat with 90% pancreatectomy, resulting in 
increased β-cell mass and improved glucose tolerance [71]. Also, the replication-inducing effects 
of exendin-4 have also been observed in human islets [72, 73]. Additional small-molecules 
acting as β-cell replication regulators, including phorbol esters, thiophene-pyrimidines, 
dihydropyridine derivatives and adenosine kinase inhibitors, have been identified through high-
throughput screening of small molecular libraries for β-cell proliferation inducers in 
immortalized β-cell lines or primary rodent islets [74, 75]. More recently, Schultz et al. identified 
a novel small molecule, WS6, increased both rat and human β-cell replication in vitro by six-fold 
in dispersed islets and by more than ten-fold in intact islets [76]. 
 Promoting endogenous β-cell replication by biological signals or small molecules is a 
promising treatment, but this method has not been applied for clinical application yet. A 
particular risk of such a strategy is the inadvertent promotion of tumorigenesis [77]. For success, 
putative molecules would have to show β-cell specificity. Also, targeted molecules would have 
to be tested with regard to their effect on other cell type within the body in order to exclude 
unwanted neoplastic effects. If we can find a way to harness endogenous β-cell replication 
without affecting other cell types, then we might develop a new therapy for diabetic patients. 
 
1.2.4. In vitro expansion of pancreatic β-cells 
 In vitro expansion of pancreatic β-cells represents an attractive strategy for obtaining a 
substantial quantity of β-cells for transplantation. Studies have demonstrated that human β-cells 
have the capacity of in vitro proliferation; however, it was generally agreed that human β-cells 
are difficult to be expanded in culture due to their low turnover rate and loss of function easily.  
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Noguchi and colleagues showed that even after culture of 48-72 hours, human islets lost half the 
islet cells, as well as dramatically decreased glucose-stimulated insulin secretion (GSIS) in vitro 
and a reduced ability to restore normoglycemia after transplantation into diabetic mice [78].  
These studies suggested that studies that are focused on identifying in vitro conditions for 
increasing the proliferative potential of adult human β-cells while maintaining their glucose-
responsive insulin secretion is critical to realizing this treatment.  
 A line of evidence divulges that different growth factors and hormones, including 
glucagon-like peptide-1 (GLP-1), parathyroid hormone-related protein (PTHrP), lactogens, 
hepatocyte growth factor (HGF), insulin, and insulin-like growth factors (IGFs) are important to 
β-cell survival and maintenance of their function in vitro [79]. Additionally, several studies have 
been focused on exploring pathways that drive β-cell proliferation while maintaining their 
function. By using in vitro and in vivo models, the delivery of transcription factors associated 
with cell cycle, such as cyclin D1 [80, 81], cyclin-dependent kinas 2 (cdk2) [82], cyclin E [82], 
cdk6 [81, 83], c-Myc [84], and hepatocyte nuclear factor-4α [85], has been shown promising for 
enhancing the replication of adult human β-cells and their functions in vitro. More recent study 
showed Wnt/GSK-3/β-catenin and mTOR signaling pathways are necessary to stimulate growth 
and proliferation of human β-cells [86, 87]. Despite the development of various strategies that 
promote the replication of β cells by using growth factors or molecules, the risk of cancer after 
transplantation would be particularly important to consider.  
 With more insights gained into the pancreas structure in the last decades, researchers 
realized that another reason for the loss of β-cell functions in in vitro culture is the change of 
cellular environment. Most β-cell expansion cultures are carried out based on monolayer culture, 
which neglects one of the important tissue niches, i.e. extracellular microenvironment essential 
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for maintaining cell functions.  In vivo, β-cells reside in a three-dimensional (3D) islet structure 
and interact directly with basement membranes in fetal and adult tissues [88]. Thus, re-
establishment of the islet-matrix relationship to mimic in vivo environment may present a natural 
stimuli for in vitro β-cell expansion. A line of studies has showed that extracellular matrix 
protects pancreatic β-cells against apoptosis and improves their insulin-secreting function [89, 
90].   However, the underlying mechanism for these improvements remains elusive.  
 Some reports suggested that β-cells cultured in vitro can dedifferentiate through 
epidermal-mesenchymal transition (EMT), a biological process in the development stage that 
allows a polarized epithelial cell to go through multiple biochemical changes and assure a 
mesenchymal cell phenotype and finally be directed redifferentiating into insulin-secreting β-
cells [91, 92]. However, the β-cell phenotype was not fully recovered, such as the new β-cells 
expressed only a fraction of their original insulin levels. Moreover, the origin of these new β-
cells derived in this way is not clear due to a possible contamination by other pancreatic cells 
which are mitotic active, e.g. duct, acinar, stromal, and endothelial cells, suggesting that these 
cells do not represent a useful source for the generation of physiological competent β-cells for 
diabetes treatments [93].  
 
1.3. Directed differentiation of hESCs towards pancreatic β cells 
1.3.1. Pancreas and β-cell development  
 In embryogenesis, three germ layers are formed during gastrulation: ectoderm, mesoderm, 
and endoderm. A thin cup-shaped sheet of definitive endoderm (DE) is formed between 
embryonic day E5 and E6 in mice. DE develops into the primitive gut tube that can be divided 
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into several region with distinct development potential and gives rise to different endodermal 
organs such as liver, lung, thymus, stomach, pancreas [94]. The first specification of pancreas 
occurs around embryonic day 8.5 (E8.5) in mice and 3 weeks in human, with the independent 
budding of the dorsal and ventral buds in the posterior region of foregut [95]. The formation of 
pancreatic bud is marked by the expression of the pancreatic and duodenal homeobox 1 (Pdx1). 
Lineage tracing studies demonstrated that Pdx1 is expressed from E8.5 until adults and Pdx1+ 
multipotent progenitors give rise to all pancreatic cells [96]. Soon later, these two buds grow into 
the surrounding mesenchymal, branch in a tree-like structure and eventually fuse after rotation of 
the gut to form definitive pancreatic endoderm around E12.5 [95]. The formation of endocrine 
progenitors is marked by the expression of transcriptional factor neurogenin 3 (Ngn3). Genetic 
lineage tracing studies showed that Ngn3+ cell exclusively give rise to pancreatic endocrine cells 
[66]. Loss of functional phenotype of Ngn3+ cells leads to the specific and complete loss of all 
pancreatic endocrine cells, while exocrine and duct compartment remain unaffected. The 
expression level of Ngn3+ reaches maximum around E15.5 and declines towards birth. 
Subsequently, the predifferentiated epithelium grows significantly in size and with distinct 
endocrine and exocrine differentiation. Endocrine cells migrate into mesenchymal and aggregate 
into islets of Langerhans. Although in the endocrine compartment, glucagon-expressing cells, 
and dual glucagon- and insulin-expression cells appear as early as E9.5, these cells do not 
contribute to mature islets of adult animals. The fully differentiated β-cells and other true 
hormone-secreting cells become evident around E13.5. At E14.5, dramatic changes in pancreatic 
development, termed as secondary transition, lead to the generation of numerous endocrine and 
exocrine cells. During the final stages of islet formation and maturation, vascularization and 
nerve innervations are frequently observed [97].  
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 Pancreas contains two types of functional compartment: endocrine and exocrine. 
Exocrine compartment occupies more than 90% of the pancreatic mass. Residing in the exocrine 
compartment, there are acinar cells that secret digestive enzymes such as lipases, carbohydrates, 
and amylases, as well as ductal cells that transport these enzymes into the duodenum [98]. 
Although hormone-secreting endocrine cells make up only 1-2% of the pancreatic cell 
population, they play an essential role in regulating glucose concentration in the body. Endocrine 
compartment harbors five different endocrine cell types residing in islets of Langerhans: insulin-
producing, glucagon (GCG)-secreting α cells, somatostatin (SST)-secreting δ cells, pancreatic 
polypeptide (PP)-secreting PP cells, and a newly found ghrelin (GHRL)-secreting ε cells. β cells 
are the most abundant cell population in the islet. In rodents, β cells make up 60-80% of the islet 
and are located in the center of islets, surrounded by other endocrine cells [99]. Human 
endocrine islets are composed of 40-60% β-cells and 30% α-cells. The β-cells are mixed with 
other endocrine cells and are distributed evenly throughout the islet structure.  
 Many of the studies took years to work on embryonic development in order to deepen our 
understanding for directed differentiation of ES cells into therapeutic β cells. Despite significant 
progress achieved in understanding pancreatic development, many aspects of pancreatic 
organogenesis are still a mystery. Therefore, studies addressing progressive lineage commitment 
mechanisms and cell fate in organogenesis are of great value and significance for understanding 
cell fate in pancreas development and directed differentiation. 
 
1.3.2. ESC-derived insulin-producing β cells 
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 After the isolation of mammalian ESCs and the establishment of in vitro culture 
conditions for maintaining their pluripotency, numerous approaches have been developed to 
generate insulin-producing β cells from ESCs. The first report of the in vitro generation of β-like 
cells was based on the selection of nestin-positive progenitor cells derived from mouse ESCs in 
2001 [100]. This approach was proposed based on the idea that adult pancreas and central 
nervous system (CNS) have similar developmental mechanisms and induced production of 
neural cells from ES cells could be adapted for endocrine pancreatic cells. However, cells 
generated by using this protocol showed low insulin production and poor insulin secretary 
response. Also, later studies showed that nestin-positive progenitor cells give rise to insulin-
producing cells as a result of uptake of exogenous insulin [101, 102].  
 In 2001, Assady et al. first reported that insulin-producing β cells can be generated from 
hESCs by spontaneous differentiation [103]. It was the first proof-of-principle study showing 
that hESCs was a potential candidate for generating β cells in vitro for cell therapy, even though 
the number of insulin-positive cells was low. As of today, many groups have claimed the 
generation of β cells from hESCs in vitro with modulated progress. The real breakthrough of 
hESCs differentiation into β cells was transformed by D'Amour and colleagues in 2006 [104], 
who first developed the stepwise approach by mimicking pancreatic organogenesis using signals 
that regulate embryonic endoderm and pancreas formation.  
 The first and most crucial step in differentiating hESCs towards pancreatic lineage is the 
specification of DE. Efficient DE differentiation is a prerequisite for generating therapeutic 
insulin-producing β cells. Studies have shown that both TGF-β and Wnt signals are critical for 
DE formation during gastrulation. Activin A, a TGF- β family member, has been used together 
with Wnt3a to effectively induce DE specification [104-106]. Recent studies showed that the 
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removal of a serum during the initial differentiation step was critical because serum components 
contain activators of the phosphatidylinositol 3-kinase (PI3K) pathway that antagonizes the 
ability of hESCs to differentiate in response to Activin A and Nodal [107]. Further studies 
revealed that the inhibition of PI3K signaling using inhibitors such as LY294002 and 
wortmannin can efficiently promote the differentiation of hESCs into DE [108, 109]. 
Approximately 70%~80% hESCs can be differentiated into DE cells under the treatment with 
PI3K pathway inhibitors, which is higher than that achieved by activin A or Nodal treatment 
alone [107]. The efficiency of DE formation can be confirmed by quantitative PCR and 
immunohistochemical staining patterns of endodermal markers including SOX17, Foxa2, and 
CXCR4. Expression of mesendoderm markers like Brachyury, spikes rapidly upon activin 
treatment and then quickly decreases when cells assume endodermal properties.  
 
1.4. Extracellular matrix (ECM) and stem cell 
 
1.4.1. The role of ECM in stem cell niches 
 Stem cells reside in a dynamic, specific microenvironment termed as ‘niche’, which 
provides extrinsic signals to control stem cell behaviors, in particular the balance between self-
renewal and differentiation. It helps sustain a stem cell pool within each tissue/organ. Since the 
concept of niche was first proposed by Scholfield in 1978 in reference to mammalian 
hematology [110], the content of the niche has increased in complexity. Generally, niches are 
composed of stem cells and supportive stromal cells, together with the ECM in which they are 
located. Also, some other factors, such as growth factors, cytokines, oxygen tension, as well as 
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physiochemical factors including pH, ionic strength, shear stress and metabolites, within niches 
are contributed to the regulation of stem cell behaviors [111]. However, the niche factors are 
highly specialized for each type of stem cells, mainly depending on the defined anatomical 
localization and function of the tissue[112]. A line of studies suggests that niches are critical for 
maintaining stem cell function and the deregulation of the stem cell niche is involved in a 
number of diseases associated with tissue degeneration, aging and tumorigenesis [113]. Thus, the 
ability to replicate in vivo stem cell niches in vitro is likely a critical requirement for developing 
fully functional cell types from stem cells. 
 ECM, a three-dimensional network of fibrous proteins and polysaccarides, has been 
recognized as an important component in niches. It plays many essential roles in regulating stem 
cell fate. The primary components of ECM are fibrous structural proteins, such as collagen, 
fibronectin and laminin, and proteoglycans such as glycosaminoglycans, heparan sulfate, 
chondroitin sulfate and non-proteoglycan polysaccharide like hyaluronic acid [114]. In living 
tissues, cells synthesize these macromolecules and deposit them into the existing matrix via 
exocytosis. However, the composition and assembly pattern of the ECM vary widely among 
tissues. The intrinsic properties of ECM, such as matrix composition, structure, and elasticity, are 
extremely spatially- and temporally-controlled, suggesting that they play a morphogenetic role in 
guiding stem cell differentiation. Studies on the dynamics of the ECM have shown that the 
interplay between cells and ECM is reciprocal [115]. As a scaffold, ECM provides anchor sites 
for cells to attach and a structural support for tissues. Cells are not only able to sense and respond 
to their outside environment, but also to change their environment's chemical and mechanical 
properties through various signal transduction pathways. These interactions further deliver 
signals to residing stem cells for guiding cell growth, differentiation, migration, survival and 
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reorganization of the resident tissue [116]. Evidences have shown that laminin is the first ECM 
protein produced in the eight-cell stage of embryos and involved in cell adhesion and migration 
during gastrulation, whereas fibronectin, collagen, and heparan sulfate glycosaminoglycans are 
produced later and assist further in germ layer differentiation and ultimate organogenesis [117, 
118]. Numbers of studies have shown that the mutation or depletion of ECM genes such as 
collagen, fibronectin, laminin, etc. can either impair tissue remodeling during embryonic 
development or result in post-natal lethal phenotypes [119-121]. Therefore, the recognition of the 
importance of ECM encourags the creation of 3D systems for growing and differentiating stem 
cells. 
 
1.4.2. ECM-stem cell interaction  
 Stem cells interact with ECM directly via cell membrane receptors, known as integrin. 
Integrins are heterodimeric transmembrane receptors composed of α and β subunits, with 
extracellular domains that bind to ECM, and cytoplasmic domains that are associated with actin 
cytoskeleton and affiliated cytoplasmic proteins, such as talin, vinculin, paxillin, and α-actinin 
[122].  Not only being as an integrated hook that couple the inside of a cell to ECM, integrins 
also transduce external signals to the cytoskeleton and recruit a number of intracellular proteins 
to ECM ligand-integrin binding sites, such as focal adhesion kinase (FAK), mitogen-activated 
protein kinases (MAPKs). The activation of these signal-transduction pathways ultimately leads 
to specialized patterns of gene expression and enforces a cellular decision on biological functions 
such as adhesion, migration, proliferation, differentiation and survival [123, 124].  
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 At least eighteen α and eight β subunits have been characterized in mammals and 
different types of integrins are involved in their ligand-binding specificities. ECM protein 
Collagen I regulates the self-renewal of mouse embryonic stem cells through α2β1 integrin [125]. 
The α6β1 integrin, a laminin receptor, is required for the adhesion of neural stem cells (NSCs) to 
their vascular niche [126]. Moreover, α6 integrin is identified as the only common element of a 
variety of "stemness" signatures on ES cells, embryonic NSCs, and hematopoietic stem cells 
[127]. An increasing body of data suggests that β1 integrin maintains stem cell niche, preserving 
a stable stem cell population by controlling the balance between symmetric and asymmetric 
division, and strictly regulating stem cell self-renewal and differentiation by modulating Notch 
activity [125, 128-130]. Therefore, it is possible to engineer integrin-dependent cellular 
interactions with ECM to control stem cell fate.  
 
1.4.3. ECM and growth factors presentation 
 Beside the ability to interact directly with stem cells, recent studies discovered that ECM 
also modulates stem cell behaviors by binding and establishing stable gradients of growth factors.   
ECM proteins like fibronectin, vitronectin, collangens and proteoglycans (PGs) themselves, or in 
combination with heparin and heparin sulphate, bind avidly to many growth factors, such as 
fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), vascular endothelial growth 
factors (VEGFs), BMPs and TGF-beta through conserved structure modules [131]. Moreover, in 
some cases, the interaction between growth factors and ECM is required for the binding of 
growth factors to their receptors on the surface of cells. The interaction of FGF and heparan 
sulfate chain is necessary for its binding to the receptor (FGFR) [132], and transforming growth 
factor-β (TGF-β) first bind to intergral-membrane PGs during signaling [133]. Alternatively, the 
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intrinsic domains within ECM proteins may act as ligands for canonical growth factor receptors 
[116]. For example, EGF-like domain from laminin [134] or tenascin [135] can bind to EGF 
receptors (EGFR) as solid-phase ligands and trigger signal as those induced by soluble ligands. 
ECM proteins degradation by proteolytic enzymes metalloproteinases can induce local release of 
intrinsic growth factor-like fragments of ECM proteins or matrix-bound growth factors from 
their insoluble anchorage. Thus, ECM acts as a sink or reservoir of growth factors (bound or 
intrinsic), which can be released to modulate the biological activities of stem cells. 
 Interaction between growth factors and ECM matrix can influence the biological 
activities of growth factors. The binding of growth factors to ECM proteins protects them from 
proteolytic degradation and increases their stability. Studies showed that heparin potentiates the 
activity of growth factor FGF by prolonging its biological half-life from 7 to 39 hours [136].  
Also, the interaction with ECM affects the diffusion of growth factors. Basic FGF diffuses 
further in the presence of heparin because bFGF-glycosaminoglycan complex partitions into a 
soluble phase rather than binding to insoluble glycosaminoglycans in ECM [137]. It is suggested 
that the complex of bFGF and glycosaminoglycan may represent one of the active forms of 
bFGF in vivo. Also, ECM functions as a physiological buffer that can trap growth factors at a 
high concentration and release it slowly for binding to its receptor [138]. This may explain why 
growth factors released over a short period of time can stimulate a long-term process like 
angiogenesis. In turn, the interaction of growth factors and ECM may provide signals to stem 
cells to modulate the expression of ECM molecules or cell surface receptors [139, 140]. It has 
been proven that TFG-β stimulates the expression of major ECM proteins such as fibronectin and 
collagen and their incorporation into the matrix [141]. Also, growth factors exert a selective 
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effect on ECM deposition by regulating the expression of matrix degrading enzymes such as 
collagenase and metalloproteinase inhibitors [140].  
 
1.4.4. ECM biomechanical properties and stem cell fate determination 
 In the stem cell niche, not only biochemical properties of ECM compositions regulate a 
balance between self-renewal and differentiation of cells, but physical and mechanical forces in 
the local stem cell microenvironment, including the elasticity or stiffness of the ECM and the 
compression forces exerted by neighboring cells, also contribute to the signaling pathways that 
are critical for cell development and differentiation. The mechanical properties of ECM are 
determined by a network of collagen, fibronectin, etc. [142].  The stiffness of a substrate leads to 
an increasing level of intracellular tension by the contraction of cytoskeletal proteins and triggers 
"pulling" forces against the matrix. Reciprocally, the forces generated inside of a cell transmit 
through adhesion proteins to their surrounding structures, and induces the adaption of their 
mechanical properties to the microenvironment. The interplay between cells and their 
microenvironment generates an isometric tension within the cytoskeleton. Together with signals 
from growth factors and morphogens, mechanotransduction pathways that involve Ras/MAPK, 
PI3K/Akt, Rho/ROCK, Wnt/β-catenin etc. finely tune the gene expression that allows the 
maintenance of cell shape and the regulation of cell behaviors [142-144]. 
 It has been discovered that matrix elasticity (or stiffness) can direct stem cell lineage 
specification. The mechanical deregulation in ECM is also found to be associated with aging, 
disease, and injury. Diseased tissues often overexpress ECM components, making the tissue 
more rigid and inhibit the cells' contractility and differentiation. For instance, the grafting of 
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MSCs after myocardial infarction fails in regenerating contracting cardiomyocytes due to scar-
like rigidity in the muscle [145], and instead it induces the trans-differentiation of these cells into 
bone-like structure in the infarcted myocardium [146]. The elasticity of cell niches varies among 
tissues, from brain tissues (0.1 kPa) to bone tissues (>30 kPa). Such natural variations in 
mechanics also occur during embryonic development, e.g. EESC < EEndoderm < EEctoderm. Thus, the 
temporal and spatial changes in ECM may guide hESCs as they mature and assemble into tissues. 
However, most studies on cell biology have been performed on a plastic dish or glass, whose 
elastic modulus is several orders of magnitude higher than nature tissues, which is one of the 
possible reasons leading to de-differentiation or loss of function in these cells in some cases. 
Thus, the development of in vitro technologies to mimic tissue elasticity would help stem cells 
mature and assemble into functional tissues. A body of studies has demonstrated that stem cell 
commitment changes in correspond to a 3D microenvironment. When human mesenchymal stem 
cells are cultured on ECM characterized by stiffness values that mimic the elastic moduli of 
brain, muscle or bone, they undergo tissue-specific cell fate into neurons, myoblasts and 
osteoblasts, respectively [147]. Also, the increasing of substrate stiffness from 0.041 MPa to 2.7 
MPa has found to be able to promote mesendodermal gene expression and terminal osteogenic 
differentiation in ESCs [148]. Moreover, the inhibition of myosin II blocks all elasticity-directed 
lineage specification, implying the physical effects of the microenvironment on stem cell 
differentiation [147, 149]. Therefore, the mechanical environment should be taken into 
consideration when engineering scaffolds or producing therapeutic cells in vitro. 
 
1.4.5. Engineering three-dimensional (3D) scaffolds for stem cell differentiation 
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 Most of stem cell studies have been performed using two-dimensional (2D) cultures. 
Even though conventional 2D cultures have provided the benefit of ease, convenience, a high 
cell viability, and also a simplified approach for understanding basic cellular behaviors. 
Nevertheless, recent knowledge on 3D microenvironments has revealed a lot of drawbacks of 
this approach. 2D culture is limited in its ability to present spatial and temporal cues to cells. 
Furthermore, the metabolism and gene expression patterns of cells are frequently altered during 
growth in 2D culture [150, 151]. Thus, 2D culture is not sufficient to reveal the real situation in 
the body. 
 The recognition of the importance of dimensionality of cellular environment has 
encouraged the creation of 3D cell culture matrices, also known as scaffolds. These scaffolds are 
porous substrates that mimic a 3D niche, providing an ideal platform for cell-cell and cell-matrix 
communications, and serving as biointeractive stages to support cell growth, migration, 
differentiation and organization. The feasibility of a 3D culture for hESCs differentiating into 
neural [152], cartilage [153], bone [154], vascular [155] and liver [156] tissue have been reported.  
Notably, ESCs in 3D cultures have been found to display higher degree of functionality and 
ability of differentiation than those cultured in a 2D culture system [157]. Moreover, hESCs that 
are differentiated in 3D matrices tend to form 3D structures similar to in vivo architecture. For 
examples, hESCs differentiated in a 3D scaffold have shown to form 3D intestinal 'organoids' 
consisting of a polarized, columnar epithelium that is patterned into villus-like structures and 
crypt-like proliferative zones expressing intestinal stem cell markers, whereas 2D culture did not 
[158]. 
 A wide range of biomaterials has been developed to for their use in 3D studies. Based on 
its properties, each biomaterial is classified as either natural or synthetic. Synthetic biomaterials 
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include polymers, ceramics, and metals. These synthetic materials offer the versatility of creating 
3D microenvironments with tunable features, such as controllable mechanical properties, 
degradation rates, porosities, and defined chemical compositions. Biodegradable poly (lactic-co-
glycolic acid) (PLGA)/poly (L-lactic acid) (PLA) polymer scaffolds have shown promoting for 
hESC proliferation and differentiation into 3D structures such as neurons, cartilage, or liver 
[159]. Many of these synthetic biomaterials, however, have poor adhesion properties due to lack 
of sites for stem cell attach and proliferate. Moreover, these materials can trigger an immune 
response. The biocompatibility of these materials is another concern for their suitability for 
transplantation in vivo [160]. The biological or chemical modification of these synthetic 
materials is thus necessary but remains challenge.  
 On the other hand, natural materials are attractive and have been frequently used for 
developing various scaffolds for stem cell studies. They consist of components either found in 
ECM, such as collagen, fibrinogen, hyaluronic acid, glcosaminoglycans (GAGs) or some other 
polysaccharides derived from plants, insects or animal components, such as cellulose, chitosan, 
dextran and alginate. Naturally derived biopolymers offer many advantageous properties that are 
favorable for stem cell studies. First, these materials are usually biocompatible and have cellular 
binding domains for cell adhesion and phenotype regulation. Second, they are intrinsically 
bioactive and can regulate stem cell behaviors orchestrated with soluble signaling factors. For 
example, adhesion to vitronectin and collagen I has shown to promote osteogenic differentiation 
[161]. In addition, in recent years, many of these natural materials, e.g. chitosan, hyaluronic acid, 
silk, Matrigel™ have been well characterized and become commercially available, with 
reproducible and controlled properties. Among ECM, collagen is the most abundant protein in 
mammals, comprising 25% - 33% of the whole-body protein mass [162]. So far, twenty-eight 
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types of collagens have been identified, specifically, type I collagen is the most frequently used 
to form hydrogels for 3D studies. 3D collagen scaffolds have been used to culture a wide variety 
of stem cells for forming different variety of tissues, such as bone, cartilage, heart, ligament, 
nerve, and vasculature. However, the use of a collagen gel for hESCs pancreatic differentiation 
has not been reported yet.  
 26 
 
Objectives and Hypothesis 
 The use of hESCs as unlimited cell sources for generating transplantable β cells has 
ignited the hope for cell-based diabetes treatment. Current studies have mostly been focused on 
stepwise hESC differentiation approaches that use cocktails of various soluble signaling 
molecules for directing hESC pancreatic lineage differentiation. However, cells generated with 
these protocols have exhibited immature pancreatic endocrine phenotypes and cannot function 
normally in vivo to correct the glucose level after transplantation in diabetic animal models. A 
major difference between β-cell in the pancreas and the β-cell generated in vitro lies in the 
different environment they reside in. Studies on pancreas organogenesis suggest that the 
development of β cells highly depend on the interaction with various physicochemical cues in 
their surrounding microenvironment. Thus, a 3D culture system would be advantageous to 
imitate in vivo stem cell niches favoring cell-cell and cell-matrix interaction.  In this work, we 
explored the feasibility of ECM-based scaffolds for enhanced pancreatic differentiation from 
hESCs.  
 We hypothesized that the pancreatic β-cell differentiation can benefit from a collagen I 
based ECM scaffold. First, we investigated whether the most critical stage in pancreatic 
differentiation—DE differentiation can be enhanced using a 3D collagen scaffold. Second, we 
examined the combinatorial effect of ECM proteins on DE differentiation from hESCs, in order 
to produce a robust protocol for endodermal lineage differentiation. Third, we examined the 
pancreatic β-cell differentiation from hESCs in collagen-based ECM scaffold. This research will 
help establish a robust protocol for generating mature β cells that can secret insulin functionally 
for cell-based diabetes treatment. 
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CHAPTER 2 
Differentiation of Human Embryonic Stem Cells into Definitive Endoderm in Type I 
Collagen Gel 
2.1. Abstract 
The production of pancreatic insulin-producing cells from human embryonic stem cells 
(hESCs) has emerged as one of the most attractive cell therapy strategies for insulin deficient 
diabetes treatment. Here, we established a three dimensional (3D) model to culture and 
differentiate hESCs that are embedded in type I collagen gel. Both single cell and cell cluster 
seeding approaches were tested. We discovered that cell clusters were formed within 3D 
collagen scaffolds no matter what seeding format was used. However, cell cluster seeding 
yielded better cell proliferation. By comparing the DE marker gene expression in cells 
differentiated within 3D collagen scaffolds and traditional 2D cell culture plates, we found that 
3D niches significantly enhanced the DE marker gene expression. The expression of Sox17, 
Foxa2, and CXCR4, three DE marker genes, in 3D cultures increased 4.5 fold, 5 fold and 4.2 
fold compared to 2D differentiation. Furthermore, our experimental results suggest that DE 
differentiation benefits from single cell seeding when forming 3D cell differentiation scaffolds.  
 
2.2. Introduction   
Embryonic stem cells (ESCs) can differentiate into any type of cells in the body. The 
generation of insulin producing cells from hESCs emerged as the most attractive alternative for 
diabetes treatment. Current knowledge revealed that the ultimate success of an in vitro approach 
to program ESCs into functional insulin-producing β-cells largely depend on the ability to 
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sequentially reproduce the individual steps that characterizes normal β-cell ontogenesis during 
fetal pancreatic development [163]. During this process, the first and the most critical step is the 
generation of definitive endoderm (DE) population, which can be further induced to adopt a 
pancreatic endocrine progenitor fate and finally differentiate into β-cells [105, 163, 164]. 
Unfortunately, many studies overlooked this principle tenet of development and thus limited the 
progress of generating physiological functioning mature cells in the end.  Therefore, it is highly 
desirable to develop an efficient and reproducible protocol on initial commitment of hESCs 
towards definitive endoderm. 
In the past decades, strategies for inducing DE cells from hESCs has been focused on the 
use of cocktails of various soluble signaling molecules such as Activin A/nodal, WNT, and FGF, 
which mimic the key biochemical signaling received by cells during ingress at the primitive peak 
in vivo [165, 166]. Although considerable progress has been made towards DE differentiation in 
vitro, a number of questions and problems remain. For example, although signaling pathways are 
conserved among many species, their particular functions (repressive or inductive) may vary 
significantly among other species and activity change with timing, explaining in part the 
contrasting findings between hESCs and mESCs or different hESC cell lines. Also, these 
methods produce heterogeneous cell population and furthermore, express pluripotent genes 
which pose a significant risk of teratoma formation and hind the further application for clinical 
use [167]. In addition, mature functional β-cells have yet to be convincingly produced in vitro 
[104, 168]. These findings indicate that the use of signaling molecules alone is insufficient to 
resemble an in vivo environment for embryonic development and there may be important factors 
are neglected in current differentiation protocols.  
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In nature tissues, cells interact not only with each other, but also with the three-
dimensional (3D) extracellular matrix (ECM). Thus, there is a growing interest in developing 3D 
scaffolds to mimic the local biochemical and mechanical 3D niche and modulate the behavior of 
stem cells [159, 169]. A line of studies have demonstrated that hESCs that were cultured on 3D 
biodegradable scaffolds showed distinct characteristics of their cell cycle and enhanced ability to 
expand and differentiate as compared to those gown on conventional two-dimensional (2D) 
culture (monolayer cultures on flat plastic cell culture plates/dishes) [156, 170]. Also, it has been 
reported that ESCs could be induced to differentiate into neural, epithelial, and endothelial 
lineages in 3D biodegradable scaffolds and form 3D tissue structures that were not observed in 
2D culture [159, 171]. 3D structure could be critical for maintaining ESCs’ native function and 
recapitulate embryonic development in vitro. The use of a 3D scaffold for ESC differentiation 
would help develop mature functional cells for cell therapy.  
 Collagens are most abundant components in the ECM and are fibrillar structural proteins. 
Due to its biocompatibility and its biodegradable property, it has been widely used as a 
biomaterial to construct 3D tissue models for investigating cell behavior and differentiation.  It 
has reported that type I collagen can enhance viability and function of many cell types, including 
smooth muscle cells, neural progenitor cells and hepatocytes [172-174]. Also, collagen I has 
been shown to improve the differentiation ability of ESCs towards different specific cell lineage 
[156, 175]. Especially, collagen I 3D culture promotes the reorganization of pancreatic endocrine 
cell monolayers into islet-like organoids as well as improves β cell survival and insulin secretion 
[176, 177]. Wang et al. showed 3D collagen scaffold promote ESCs into pancreatic β-cell 
lineage specification in a mouse cell model [178]. Thus, it has been widely accepted that both 
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chemical and physical factors, as well as geometric or topographical features of 3D scaffold, 
contribute collectively to modulate the differentiation of stem cells into specific lineage.  
 In this study, we hypothesized that the 3D collagen culture may benefit for hESC 
proliferation and directed differentiation towards definitive endoderm, thus helpful for 
establishment of a rigorous, standard protocol of fully functional insulin-producing β cells for 
islet transplantation. 
 
2.3. Materials and Methods  
2.3.1. hESC culture 
Undifferentiated hES cell line, H9, was acquired from Wicell Research Institute 
(Madison, WI). Cells were cultured on mitotically inactivated mouse embryo fibroblasts (MEFs)  
feeder layers in DMEM/F12 medium (HyClone) supplemented with 20% (v/v) Knockout serum 
replacement (KOSR, Gibco), 2 mM L-glutamine (Cellgro), 0.1 mM 2-mercaptoethanol (β-ME, 
A.G. Scientific), 1 mM non-essential amino acids (Invitrogen), and 4 ng/ml basic FGF (bFGF, 
Peprotech).  Cells were passaged at a 1:4~1:6 split ratio every 4~7 days through collagenase IV 
(1 mg/ml, Sigma) treatment combined with manual dissociation. Before use, cells were 
transitioned from feeder-dependent culture to feeder-free culture to eliminate MEF feeder cells. 
Briefly, cells were seeded on Matrigel (BD biosciences)-coated plates in mTeSR1 medium 
(StemCell Technologies, Vancouver, Canada) and maintained in an undifferentiated state under 
feeder-free conditions. Cultures were passaged at a ratio of 1: 3~1:5 every 3~5 days cells using 1 
mg/ml dispase (StemCell Technologies, Vancouver, Canada). The cultures were incubated at 
37oC in the atmosphere supplemented with 5% CO2. The cell culture media exchanged daily. 
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2.3.2. 3D hESC definitive endoderm differentiation  
 3D scaffolds were prepared as follows: a type I rat tail collagen solution  (BD 
Biosciences) was first diluted with sterile water and 10X phosphate-buffered saline (PBS, 
Cellgro) to achieve a final collagen concentration of 1.67 mg/ml. The pH of the diluted collagen 
solution was then adjusted to 7.4 using 1 N NaOH. The solution was subsequently chilled on ice 
to prevent from gelation. At the same time hESCs were treated with AccutaseTM (Millipore) or 
dispase (1 mg/ml) (StemCell technology) in order to obtain single cells or cell clusters 
suspension. The enzyme treated cells were suspended in 10× DMEM medium (maintaining 
physiologic osmolarity at 250~300 mOsM) and then added to the ice-chilled collagen solution to 
achieve a final collagen concentration of 1.5 mg/ml and the cell density of 2.5 × 106 cells/ml. 
Thereafter, 0.4 ml aliquots of the cell-collagen mixture were transferred into wells of a 24-well 
tissue culture plate and incubated at 37oC, 5% CO2 for 30 min to form scaffolds. Once a scaffold 
has formed, 0.5 ml of the cell culture medium was added to the top of the scaffold.  The cell-
laden scaffolds were then placed into a CO2 incubator and allowed cells to grow for 24 hours 
before initiating DE differentiation.  
DE differentiation was carried out by following a protocol developed by D’Amour et al. 
[104]. In brief, hESCs were washed briefly with PBS+/+ (Cellgro) before initiating the 
differentiation and then cultured in RPMI 1640 medium (Gibico) supplemented with 
recombinant growth factors 100 ng/ml Activin A (PeproTech Inc.) and 25 ng/ml Wnt3a 
(PeproTech Inc.) for 1 day. After 24 hours, the medium was replaced with a fresh RPMI 1640 
medium supplemented with 0.2% defined FBS and 100 ng/ml Activin A. The differentiation 
continued for another 72 hours.  
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2.3.3. Scanning electron microscopy (SEM) 
Cell-collagen scaffolds were fixed with 2.5% (v/v) glutaraldehyde (EM Sciences, Fort 
Washington, PA) at pH 7.4 for 2 h. After washing with PBS each for 10 min three times, the 
scaffolds were post-fixed in 2% osmium tetroxide (EM Sciences) for 2 h and dehydrated with 
25%, 50%, 75%, 85%, 95%, and 100% (v/v) of ethanol before lyophilization. The lyophilized 
scaffolds were mounted on aluminum stubs with a double-stick carbon tape and sputter coated 
with gold before SEM, using a Jeol Field Emission scanning electron microscope (JSM-6335F; 
JEOL USA, Peabody, MA) at an accelerating voltage of 10 kV. 
 
2.3.4. Cell viability assay within 3D collagen scaffolds 
The cell viability within a collagen scaffold was determined using calcein-AM/ 
propidium iodide (PI) staining kit (Falcon) by following the manufacture's instruction.  The kit 
contains two fluorescent probes that measure cell viability. Live cells are stained with green 
fluorescence due to the enzymatic conversion of the nonfluorescent, cell-permeate dye calcein-
AM to the intensely fluorescent calcein (excitation: 495 nm, emission: 515 nm). Dead cells are 
identified by staining with PI, which enters cells with damaged membranes, and, upon binding to 
nucleic acids, produces a bright red fluorescence (excitation: 495 nm, emission: 635 nm). PI is 
excluded by the intact plasma membrane of live cells. Live/dead staining was prepared with 2 
mM calcein AM and 4 mM PI in PBS. Form assessment of immobilized cells, 0.2 ml of the dye 
solution was added to 0.4 ml scaffold samples. The samples were incubated with the dyes 
(calcein AM and PI) for 10 min. The dye solution was removed and 0.5 ml of PBS was added 
and incubated for another 30 min. The PBS buffer was subsequently removed in order to 
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stabilize the cell containing scaffold before taking microscopy images with an Olympus upright 
fluorescence microscope (IX71, Tokyo, Japan) equipped with a supersensitive CCD camera 
(mode number ROLERA-XR, Surrey, BC, Canada) controlled by an imaging analysis software 
Slidebook (Intelligent Imaging Innovations, Inc., Denver, CO).  
 
2.3.5. AlamarBlue cell proliferation assay 
The proliferation of hESCs and their derived cells during DE differentiation within 3D 
scaffolds was determined using an oxidation–reduction indicator alamarBlue (Alamar 
BioSciences, Sacramento, CA) agent that reacts to viable cells, generating fluorescence to 
detection. To evaluate cell proliferation within the collagen scaffolds during DE differentiation, 
we inoculated the scaffolds with 2.5×106 cells/ml hESCs. hESCs were differentiated into DE 
cells, as described above. At specified time intervals, 400 µl of differentiated medium containing 
10% alamarBlue was added to each well after washing the scaffolds once with PBS buffer and 
the plate was incubated at 37°C for 4 hrs. The fluorescence of the cell culture broth was 
measured by fluorescence spectrophotometer using a fluorescence excitation wavelength of 540–
570 nm (peak excitation is 570 nm). Read fluorescence emission at 580–610 nm (peak emission 
is 585 nm).  All measurements were performed at room temperature. Finally, results were 
analyzed by plotting fluorescence intensity versus a duration time. 
 
2.3.6. RNA extraction and quantitative RT-PCR (qRT-PCR) 
Total RNA was extracted from cultured cells using the RNeasy Plus Mini kit (Qiagen, 
Valencia, CA). RNA samples were digested with DNase I (1 unit per µg RNA, Promega 
Corporation, Madison, WI) prior to reverse transcription (RT) to remove any contaminated 
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genomic DNAs. A portion of 1 µg of RNA was used to prepare cDNA. The reverse transcription 
was performed using ProtoScript® First Strand cDNA Synthesis Kit (New England Biolabs). 
Quantitative PCR was carried out using Realplex Real-Time PCR machine (Eppendorf). The 
PCR reaction solution consisted of 10 µl of SYBR Green PCR master mix (Roche), 0.15 µl of 10 
mM forward and reverse primers that are specific to the target marker genes, 7.7 µl of nuclease-
free water, and 2 µl of diluted template cDNA in a total volume of 20 µl. Initial enzyme 
activation was performed at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 
15 s, and primer annealing/ extension at 60°C for 1 min. Melting curve analysis was performed 
at 95°C for 1 min, 60°C for 30 s and 95°C for 30 s. The relative expression level of each gene 
was normalized against a house-keeping gene, β-actin. RNA samples collected from 
undifferentiated hESCs served as control. Primer sequences were summarized in Table 1. Each 
experiment was carried out in triplicate. 
 
2.3.7. Statistical analysis 
All experiments were carried out at least in triplicate. Unless otherwise indicated in the 
text, all analytical measurements were repeated three times. All data were expressed as means ± 
standard deviations. Statistical analysis was performed with Student’s t-test, with p<0.05 
considered as statistically significant. 
 
 
2.4. Results 
2.4.1. hESC maintenance on two culture system 
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As shown in Figure 1, undifferentiated hESCs grown on MEF feeder layer (A-C) and 
Matrigel (D-F) showed as compact, multicellular colonies. Also, they exhibited a high nuclear-
to-cytoplasm ratio and prominent nucleoli, which is a characteristic feature of hESCs. After 5 
passages of culture, the expressed of SOX2, SSEA4, and TRA-1-60 were stained positively 
(Figure 1. G-I), indicating the pluripotency of the hESCs. 
 
2.4.2. Collagen I scaffold characterization 
Unseeded and hESC seeded collagen I scaffolds were characterized morphologically by 
SEM micrographs (Figure 2). The microscopic structure of a collagen scaffold showed a 
homogeneous fibrillar and porous 3-D network, indicating spacious areas for cell growth and 
differentiation. The diameter of the collagen nanofibers was 230 nm on average and pore size 
was about 0.65 µm3 estimated using NIH Image J software. SEM micrographs of seeded 
scaffolds showed that the hESCs were tightly attached to the scaffolds and secreted ECM-like 
proteins (Figure 2B), suggesting the suitability of the collagen type I scaffold for hESC growth. 
 
2.4.3. Morphological and viability analysis of DE differentiated hESCs within collagen 
scaffolds 
The study aimed to compare the viability and proliferation between two different cell 
seeding methods, i.e. single cell vs. cell cluster seeding. Cell morphology and viability were 
monitored. It was found that cells remained single on day 2 of seeding within collagen scaffolds 
when the single cell seeding approach was applied (Figure 3A). The formation of cell clusters 
was observed with the progression of differentiation (Figure 3B). In contrast, cells started 
forming aggregates on day 2 when the cell cluster seeding approach was used (Figure 3C), and 
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the size of cell clusters increased significantly on day 4 post differentiation (Figure 3D). The cell 
viability within 3D collagen scaffolds was approximately 98% during the time period of 
differentiation (Figure 3E-3H). These results suggest that both single and cluster hESCs can 
survive and proliferate within the 3D collagen scaffolds. 
 
2.4.4. Proliferation rate of DE differentiated hESCs within collagen scaffolds 
To examine cell growth during differentiation, the cell-laden scaffolds were incubated 
with the AlamarBlue substrates for 4 h and the fluorescence of solution was measured, which 
indicated the cell proliferation rate. As revealed in Figure 4, cell proliferation rate was 3-fold 
higher within a collagen scaffold when the cluster seeding approach was used as compared to 
single cell seeding approach.  
 
2.4.5. hESC DE differentiation in 2D and 3D  
We then investigated the directed differentiation of hESCs to DE within collagen 
scaffolds. For inducement of the DE differentiation, hESCs were seeded into collagen scaffolds 
as either single cells or cell clusters, and grown in a DE differentiation medium for 4 days. The 
expression of DE markers: Sox17, Foxa2 and CXCR4 in the induced cells on day 2 and day 4 
were detected to ascertain whether the hESCs were differentiated into DE concomitantly with 
their proliferation within collagen scaffolds. Undifferentiated hESCs served as a control for the 
assay. As shown in Figure 5, analysis of gene expression showed that the treated samples, which 
were differentiated for 4 days under treatment of 100 ng/ml activin A and 25 ng/ml Wnt3a, 
expressed DE markers SOX17, FOXA2, CXCR4 in both 2D and 3D culture, which confirmed the 
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generation of definitive endoderm from hESCs.  Especially, 3D culture by using both cell 
seeding methods significantly increased the expression level of DE markers as compared to 2D 
culture, however, the single cell seeding approach resulted in higher expression level of DE 
markers (SOX17>250-fold, FOXA2 >500-fold, and CXCR4 >1000-fold on day4 as compared to 
undifferentiated hESCs) than cell cluster seeding approach (SOX17>100-fold, FOXA2 >300-fold, 
and CXCR4 >500-fold on day4 as compared to undifferentiated hESCs). Meanwhile, significant 
decreases of OCT4 on day4 after induced differentiation in both 2D and 3D cultures indicated 
the loss of pluripotency of hESCs. In addition, the cells in 3D scaffold showed a decreased level 
of ectoderm marker PAX6 and mesoderm marker Brachyury, indicating the DE differentiation 
was dominant in the cultures.   
 
2.5. Discussion 
DE differentiation is critical for hESC pancreatic lineage differentiation. In our previous 
study, we demonstrated that more mature insulin-producing β cells could be generated from 
mouse ESCs (mESCs) when differentiating them within a collagen scaffold [179]. In this work, 
we investigated the feasibility of differentiating hESCs into matured β cells. As the DE 
differentiation is critical to the hESC pancreatic lineage specification, we investigated its 
differentiation within a 3D collagen scaffold. We found that the cell proliferation rate and DE 
differentiation efficiency are significantly affected by the seeding approach. The experimental 
results suggested that cells proliferated much faster when they were seeded in clusters, as 
compared to those seeded in single cell suspension. Also, DE differentiation was greatly 
enhanced in 3D culture, especially when single cell approach was applied. To the best of our 
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knowledge, this study was the first to explore the feasibility of differentiating hESCs into 
endoderm lineage in 3D collagen scaffold.  
3D culture provides a means to study hESCs growth and differentiation in a 
physiologically relevant manner in vitro. The ideal scaffold for tissue engineering would have a 
structural component to provide mechanical support and a network structure consisting of large 
pores to allow cell expansion and the diffusional transport of nutrient and waste molecules [179]. 
Collagen scaffold is an ideal candidate for hESCs encapsulation and differentiation because it 
has relatively large pores (Figure 2A), support cell attachment, its gel formation is simple [180]. 
From SEM images (Figure 2B), collagen has shown to support cells attachment via cell-
extracellular matrix interaction. Also, hESCs grown in 3D environment showed formation of 3D 
aggregates structure, as revealed in bright field images, which was not observed in conventional 
2D culture. We think the pore size, fibrillar density and organization of the collagen fibers favor 
cell migration and promote the formation of aggregates structures in the process of hESCs 
differentiation. 
It is crucial to maintain hESC viability while perform differentiation process. Therefore, 
we cultured hESCs in growth medium for 24 hours and initiated hESC DE differentiation using 
Activin A and Wnt3a on day one of seeding, which will prevent apoptosis of hESCs after cell 
dissociation. As shown here, collagen scaffold was capable of maintaining hESCs viability in the 
process of differentiation by using both cell seeding methods.  
To determine whether DE can also be efficiently derived from hESCs in 3D collagen gel, 
single cell and cell cluster preparations of hESCs were induced to differentiate in 2D or 3D 
cultures following a well-established differentiation protocol. It is important that hESCs seeded 
within the scaffolds maintain their pluripotency prior to differentiation. The pluripotency related 
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gene Oct4 was decreased by the process of definitive endoderm differentiation accompanied by a 
transient expression of mesendoderm marker, Brachyury, 24 hours after activin A and Wnt3A 
treatment (day 2 after inoculation), which indicated the hESCs proceeded through the mesoderm 
to endoderm transition. Moreover, the embedded cells in collagen gel expressed much higher 
definitive endoderm marker genes level compared to 2D culture when they reached their peak on 
day 4 after differentiation, with SOX17 increase around 4.5 fold, FOXA2 around 5 fold and 
CXCR4 around 4.2 fold as compared to 2D culture. Interestingly, the expression of DE gene of 
differentiated cells seeded as clusters did not increased as significantly as those cultured as single 
hESCs. The enhanced efficiency of hESC differentiation into DE by single cells seeding could 
be explained by proper infiltration of single cells into the pores of the scaffolds, which would 
provide relatively uninhibited access of media and growth factors to the cells. Also, we observed 
some outgrowth of cells when hESCs were seeded as cell clusters in collagen gel, which 
probably inhibit the grow factor diffusion and slow down the differentiation process. However, 
the proliferation rate in 3D culture by using single cells seeding was lower than cell clusters 
seeding. The possible reasons could be differentiation could be easily started from single cells 
which slow down their proliferation.  
In summary, we have established a 3D culture model to differentiate hESCs into 
definitive endoderm, which is most critical stage for pancreatic differentiation. The seeded 
hESCs proliferated and maintained high viability in the collagen culture. Upon directed 
differentiation, the seeded hESCs can be differentiated into DE with a higher efficiency when 
cells were seeded as single cells. This system may provide an alternative strategy for generating 
insulin-producing cells for cell-based diabetes treatment 
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Chapter 3 
Combinatorial Effect of ECM Proteins on 3D Human Embryonic Stem Cells Definitive 
Endoderm Differentiation 
 
3.1. Abstract 
hESCs are potential renewable cells sources for cell-based therapies. Here, we reported a 
novel three-dimensional (3D) model to derive DE cells from hESCs by using collagen I and 
various ECM proteins such as fibronectin (FN), laminin (LN) and vitronectin (VN). It is found 
that, single ESCs formed clusters and remained a high viability (>95%) within collagen scaffolds. 
More importantly, demonstrated by qRT-PCR, immunohistochmical staining, flow cytometry 
results, mixture of ECM proteins by incorporating of FN, LN and VN together in 3D collagen 
matrices produced more than 90% of SOX17+ DE cells with DE markers genes  Sox17, Foxa2 
and CXCR4 increased by 79-fold, Foxa2 60-fold and CXCR4 75-fold respectively  Also, the cells 
in collagen-ECM scaffold secreted more ECM proteins such as fibronectin 1, laminin gamma 1, 
collagen type IV alpha 1, collagen type III alpha 1, collagen type I alpha 2 as showed by qRT-
PCR. Immunohistochemical staining showed that more collagen IV produced in collagen 
scaffold with addition of ECM protein mixture. The method described here presents a significant 
step towards the efficient generation of DE cells for use in regenerative medicine and drug 
discovery, as well as a platform for studying cell fate specification during development. 
 
3.2. Introduction 
It has proven to be a challenge that ES cells are directed to differentiate into pure 
endodermal populations in vitro [181, 182], likely because the organ development requires a 
strict temporal and spatial control at each stage. It is well known that extracellular matrix (ECM) 
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is a key component in stem cell niches and plays an important role in cell adhesion, migration, 
proliferation, and differentiation [183]. ECM not only provides a support for cells and tissues, 
but can also bind to growth factors, cytokines, and other soluble signaling molecules and 
transduce them to cytoskeleton to trigger signaling transduction pathways and ultimately affect 
gene expression, thereby changing the fate of cells [123, 184, 185]. Consequently, it is critical to 
mimic this in vivo environment when designing an in vitro hESC differentiation system.   
In this chapter, we showed that DE differentiation can benefit from the use of collagen 
scaffolds which offer 3D environments that allows cell-cell and cell-ECM interaction. While 
collagen is a good biomaterial for fabricating a hydrogel scaffolds, it is interested in determining 
whether the DE differentiation can be further improved if other ECM proteins are mingled with 
collagen when fabricating scaffolds.  It has been known that non-collagenous ECM proteins such 
as laminin (LAM), fibronectin (FN), and vitronectin (VN) also play important roles in cell 
adhesion, migration, proliferation, and differentiation. FN is widely expressed by multiple cell 
types and is critically important during embryogenesis [186]. George et al.’s work demonstrated 
that the disruption of FN gene in ESC resulted in defects in mesoderm, neural and vascular 
development [187]. In addition, it has shown that FN was acquired when ESCs differentiated 
into endoderm [188] as well as many endoderm-derived tissues such as lung and pancreas [189, 
190]. LM, a family of glycoproteins, is the major constituent of basement membranes between 
primitive ectoderm and endoderm. By interacting with cells mediated by integrins, dystroglycan, 
and other cell surface receptors, LM contributes to cell survival, phenotype maintenance, and 
differentiation [191]. Specifically, LM is upregulated during endoderm epecification [192]. Also, 
Lin et al. demonstrated that the differentiation of insulin-producing cells (IPCs) from human 
mesenchymal stem cells could be enhanced when LM and FN are used [193]. Another study also 
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revealed that collagen 3D scaffolds prepared in combination with adhesive ECM proteins, such 
as FN and LM, offer better cues for mesenchymal stem cell neuron differentiation, even without 
the use of chemical differentiation factors [194], suggesting that ECM proteins can provide 
signals for directing cell differentiation. Vitronectin (VN) is another widely distributed high 
molecular weight glycoprotein found in most sites of ECMs and is known to promote cell 
adhesion, migration, differentiation, and cytoskeletal organization. It affects cell morphology as 
well. VN has been identified in fetal islet tissue emerging from pancreatic ducts during 
development, suggesting its role in DE specification [195]. It has been proved that the addition 
of VN in gel condition significantly improves β-cell survival and insulin secretion [177]. Even 
though a lot of studies have been carried out to investigate the influence of ECM proteins on cell 
behavior and differentiation, there have been few reports on endoderm-derived cell 
differentiation. 
Here, we choose collage type I as a major component of the scaffold combined with 
various ECM proteins such as LAM, FN, and VN to investigate the combinatorial effect of these 
components on DE differentiation within collagen scaffolds.  
 
3.3. Materials and methods 
3.3.1 3D hESC culture 
The hESC line H9 was acquired from Wicell Research Institute.  Cells were maintained 
in an undifferentiated state on growth-factor-reduced Matrigel (BD Biosciences, Bedford, MA)-
coated cell culture plates in mTeSR1 medium (StemCell Technologies, Vancouver, Canada). 
Cells were passaged every 3~5 days at a splitting ratio of 1: 4~1:6 through dispase (1 mg/ml) 
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(StemCell Technologies, Vancouver, Canada) treatment combined with manual dissociation. The 
cells were incubated at 37oC in the atmosphere supplemented with 5% CO2. The cell culture 
media was exchanged daily. 
3D scaffolds were prepared as follows: type I rat tail collagen solution (BD Biosciences, 
Bedford, MA) was diluted with sterile H2O and 10× phosphated-bufferd saline (PBS) (Mediatech 
Inc., Manassas, VA) to maintain the physiologic osmolality at 250~300 mOsm. The final 
collagen solution concentration was 1.5 mg/ml. To produce ECM protein mixed collagen 
scaffolds, collagen gel solution was added with variable amounts of FN (BD Biosciences, 
Bedford, MA), LM (Trevigen, Gaithersburg, MD), or VN (Trevigen, Gaithersburg, MD) stock 
solution to final concentration of 25, 25, and 4 μg/ml, respectively. The pHs of these solutions 
were adjusted to 7.4±0.2 by the addition of 1 N sterile NaOH. These solutions were chilled on 
ice to prevent from gelation until use. 
  Before seeding hESCs into scaffolds, the ROCK inhibitor, Y-27632 (Calbiochem, 
California, USA) was added to the cell cultures at 10 µM for 2 hrs before the cells were 
dissociated by AccutaseTM (EMD Millipore, Billerica, MA) treatment. The single cell suspension 
was obtained after centrifugation at 300 x g for 5 min and suspended in mTeSR1 medium. The 
live cell number was determined by trypan blue staining assay using a hematocytometer. The cell 
suspension was then added to the ice-chilled collagen solution along with different ECM proteins 
to achieve a final cell density of 2.5 × 106 cells/ml. Thereafter, 0.4 ml aliquots of the cell-
collagen with ECM protein mixtures were transferred into wells of 24-well tissue culture plates 
and incubated at 37oC, 5% CO2 for 30 min to 1 h to achieve gelation. 0.5 ml of cell culture 
medium (mTeSR1 with 10 µM Y-27632) was added to the top of the scaffolds once the scaffolds 
have formed. The cell-laden scaffolds were returned to the incubator and allow cells to grow 
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within the scaffolds for 24 hrs before initiating differentiation. In two-dimensional (2D) cultures, 
cells were plated onto Matrigel-coated tissue culture plates at the same density, followed by 
same differentiation procedure as 3D cultures do.  
 
3.3.2. hESC DE differentiation 
The DE differentiation was optimized by differentiating hESCs in two different DE 
medium: (1) hESCs were fed with RPMI 1640 medium (Invitrogen) supplemented with 100 
ng/ml activin A (PeproTech Inc.) and 25 ng/ml Wnt3a (PeproTech Inc.) for 1 day and after 24 
hours, medium was replaced with fresh RPMI 1640 medium supplemented with 0.2% defined 
FBS and 100 ng/ml activin A for another 72 hours (medium A). (2) hESCs were fed with 
DMEM/F12 medium supplemented with 0.2% BSA (Sigma), 0.5% B27 (Invitrogen), 0.5% N2 
(Invitrogen), 100 ng/ml activin A (PeproTech Inc.) and 25 nM wortmannin (EMD Millipore) for 
4 days (medium B). The DE differentiated efficiency will be compared and the medium that 
resulted in higher DE efficiency would be used for DE differentiation in 3D culture experiments. 
 
3.3.3. Cell viability  
The cell viability within scaffolds was determined using live/dead cell dual staining kit 
(Sigma-Aldrich, Saint Louis, MO) by following the manufacture’s instruction. The kit contains 
two staining probes for the simultaneous detection of viable and dead cells. Live cells with 
intracellular esterase activity can convert the nonfluorescent, highly lipophilic, cell-permeable 
dye calcein-AM into the fluorescent dye calcein which emits green fluorescence (excitation: 495 
nm, emission: 515 nm). Dead cells are identified by a nuclei staining dye PI which passes 
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through damaged cell membranes, and upon binding to DNA double helix, producing red 
fluorescence (excitation: 495 nm, emission: 635 nm). PI is excluded by the intact plasma 
membrane of live cells. After washing with PBS three times, cell-laden scaffolds were incubated 
with 200 µl of the live/dead staining solution at 37oC for 15 min. The excess dye solution was 
removed afterwards and 0.5 ml of PBS was added on the top of the scaffold. Excess buffer was 
subsequently removed in order to stabilize the cell-laden scaffolds for imaging. Samples were 
examined under an Olympus upright microscope (IX71, Tokyo, Japan) equipped with a 
supersensitive CCD camera (mode number ROLERA-XR, Surrey, BC, Canada) controlled by an 
imaging analysis software Slidebook (Intelligent Imaging Innovations, Inc., Denver, CO). 
 
3.3.4. Scanning electron microscopy (SEM) 
3D samples were washed with Dulbecco’s phosphate buffered saline (DPBS) buffer for at 
least 3 times to remove all proteins in the culture medium or other impurities. The scaffolds were 
then fixed with 2.5% (v/v) glutaraldehyde (EM Sciences, Fort Washington, PA) in PBS buffer at 
pH 7.4 for 2 h at room temperature. After three 10-min washes in PBS, the samples were post-
fixed with 1% osmium tetroxide (EM Sciences) for 1 h at room temperature. Followed by two 
10-min washes, the fixed scaffolds were dehydrated in a series of graded ethanol: 30%, 50%, 
70%, 90% and two times of 100% v/v for 10 min each. Then, the cell-laden scaffolds were 
allowed to dry overnight on aluminum foil in fume hood. The dried scaffolds were mounted on 
SEM sample stages using double-stick carbon tape and sputter coated with gold-palladium 
before examination. Finally, the specimens were analyzed using a FEI/Philips XL30 FEG ESEM 
(FEI, Hillsboro, OR) at an accelerating voltage of 10 kV. 
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3.3.5. Total RNA extraction and quantitative RT-PCR  
To detect gene expression in cells grown in 2D or 3D cultures, the total RNA was 
extracted from cultured cells using a RNeasy Plus Mini kit from Qiagen. Prior to reverse 
transcription (RT), RNA samples were digested with DNase I to remove contaminated genomic 
DNA. 1 µg of RNA was used to synthesize cDNA. Reverse transcription was performed using a 
High Capacity cDNA Reverse Transcription Kit from the Invitrogen followed by the 
manufacture’s instruction. Quantitative real-time PCR (qRT-PCR) was carried out using the 
Power SYBR Green PCR master mix (Applied Biosystems) and was performed on the Realplex 
Real-Time PCR system (Eppendorf, Realplex4 model). Initial enzyme activation was performed 
at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 15 s, and primer 
annealing/extension at 60°C for 1 min. Melting curve analysis was performed at 95°C for 1 min, 
60°C for 30 s and 95°C for 30 s. The relative quantification was performed against a standard 
curve and quantified values were normalized against the house-keeping gene β-actin. 
 
3.3.6. Flow cytometry 
For 3D culture, hydrogels were digested by using 2 mg/ml collagenase solution (Life 
Technologies) for 30 min at 37oC. After centrifugation at 300 x g for 5 min and aspiration of 
supernatant, the cells were then treated with 0.25% typsin with EDTA (sigma) to further digest 
the cells into single cell suspension. Cells were filtered through 70 mm cell strainer (BD 
FalconTM) to remove the clumps. For 2D culture, cells were dissociated using AccutaseTM cell 
detachment solution (Millipore) for 5 min followed by removal of trypsin by centrifugation. 
Cells were fixed with 4% paraformaldehyde and permeabilized with ice-cold methanol. Cells 
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were labeled with PE mouse anti-human Sox17 (BD Biosciences) at 5 µl per 1 × 106 cells for 45 
min at room temperature in the dark. Cells labeled with PE mouse IgG1ĸ was used as an isotype 
control. Cells were washed three times and resuspended in PBS with 10% inactivated FBS and 
0.09% sodium azide. Samples were acquired on a Becton-Dickinson fluorescence activated cell 
sorter (FACS) Calibur 4-color flow cytometer and data analyzed using Bection-Dickinson 
CellQuest software. Data were gated using forward and side scatter to eliminate debris and the 
resulting histograms plotted to reflect the mean fluorescence intensity of Sox17 versus IgG1ĸ 
isotype control. 
 
3.3.7. Immunohistochemical and immunocytochemical staining 
The cryosectioning of cell-laden scaffolds was performed as described elsewhere [196]. 
In brief, the scaffolds were fixed using 10% neutral-buffered formalin solution (NBF) for 3 hrs.  
After overnight infiltration with a series of 20% sucrose and sucrose/OCT® solution, the 
scaffolds were placed in a peel-away mold (VWR, south Plainfield, NJ) in tissue freezing 
medium (Tissue-Tek OCT Compound, Sakura-Fintek). All the molds were then placed into the 
MICROM cryostat (Richard-Allan Scientific) chamber and the samples were allowed to freeze at 
-20oC for at least 30 min. Routine frozen sectioning was performed by collecting 8-µm sections 
onto positively charged slides. The scaffold sections were either collected or air-dried for a 
minimum of 30 min. Before staining, sections were hydrated in PBS for 10 min and then 
incubated in a blocking buffer (PBS containing 5% normal goat serum, 0.3% Triton X-100) for 1 
h and thereafter in primary antibodies for 12 h at 4°C diluted in the blocking buffer. The primary 
antibodies used in this study were mouse monoclonal anti-human Sox17 (R&D Systems; 1:50), 
rabbit monoclonal anti-Foxa2 (Abcam; 1:1000), rabbit anti-Collagen IV (Abcam; 1:200). The 
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secondary antibodies used were DyLightTM 488 conjugated goat anti-mouse IgG (Thermo 
Scientific; 1:500) and Rhodamine (TRITC)-conjugated donkey anti-rabbit IgG. To stain 2D 
culture samples, cells seeded on Matrigel-coated plates were fixed with 4% paraformaldehyde 
(Sigma). After being treated in the blocking buffer for 45 min at room temperature to inhibit 
nonspecific binding, cells were labeled with primary and secondary antibodies as described 
above. DAPI (Research Organics) were used to counterstain cell nucleus. Images were captured 
using an inverted fluorescence microscope (Olympus, IX71, Japan).  
 
3.3.8. Statistical analysis 
All experiments were carried out at least in triplicate. All quantitative values were 
presented as mean ± SD. Statistical analyses were performed using student’s t-test and p-value 
≤0.05 were considered statistically significant. 
 
3.3.Results 
3.4.1. PI3K inhibitor enhanced DE differentiation from hESCs  
Generating appropriate DE population is a crucial step in producing derivative lineages 
and functional cell population. Most protocols use Activin A and Wnt3a described by D’Amour 
[104] to generate DE cells. Recent studies found out PI3K signaling was evolved in DE 
differentiation, here we tested whether the addition of wortmannin, a PI3K inhibitor, would 
improve our DE protocol. The qPCR results showed that the addition of wortmannin was able to 
augment the expression of DE markers SOX17 and FOXA2 by 8-fold and 13-fold, respectively, 
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as compared to D’Amour’s protocol (Figure 6A). Low expression of pluriopotency marker 
(OCT4), mesoderm (Brachyury) and ectoderm (PAX6) lineages marker provided evidence that 
wortmannin can enhance DE differentiation. Also, the differentiation efficiency was evaluated 
by flow cytometric analysis of SOX17+ cells, revealing that the percentage of SOX17+ cells was 
70% when cells were treated with Activin A in combination with PI3K inhibitor as compared to 
32% when cells were treated with Activin A in combination of Wnt3a.  Consistent with the gene 
expression and flow cytometric analysis, immunostaining revealed that larger population of cells 
were stained both SOX17 and FOXA2 positive when cells treated with wortmannin in 
combination with Activin A. Taken together, these finding indicated that the inhibition of PI3K 
pathway does significantly promote differentiation of hESCs into endocrine lineage. 
 
3.4.2 Proliferation and morphological changes of hESCs-differentiated DE cells within scaffolds 
To reveal the potential of ECM-collagen scaffolds for directing hESC pancreatic lineage 
differentiation, undifferentiated single suspended cells were seeded into collagen along with 
ECM proteins (for 3D cultures) or onto Matrigel-coated cell culture plates at a cell density of 2.5 
× 106 cells/ml (for 2D cultures). Cells grown in either 2D or 3D cultures both proliferated rapidly 
but differed in their morphology (Figure. 7). In 2D culture, cells were predominantly flat, 
stretched endoderm-like cell morphology throughout the entire differentiation period. In contrast, 
cells formed clusters after 2 days of differentiation in 3D cultures (Figure. 7). The number of 
cells and the size of clusters increased significantly. The spherical tissue-like structures were 
formed on day 4 of DE differentiation. Interestingly, within the collagen gel matrix containing 
VN, cells exhibited a highly elongated branch like junctions without forming significant clusters.  
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The viability of differentiated DE cells within scaffolds was determined on day 2 and day 
4 by calcein-AM/PI live/dead cells dual staining. As shown in the fluorescence images (Figure. 
8), there appear to be a high percentage of live cells (green) with only fewer dead cells (red), 
mostly found along the side of the cluster. The average size of the cell clusters was about 150-
250 µm. The live/dead staining also permitted the observation of the high percentage of live cell 
clusters with outgrowth and cluster-cluster connection. These results demonstrated that the 
dissociated hESCs could be immobilized in collagen along with ECM proteins with a high 
viability.  
 
3.4.3. Morpholigical analyses of DE differentiated cells in 3D collagen-ECM scaffolds 
To characterize the in vitro environment of the 3D scaffolds for hESC differentiation, we 
examined the structure of collagen-ECM scaffolds and the morphology of DE differentiated cells 
within these scaffolds by means of SEM. The collagen-ECM scaffolds showed similar 
microscopic structure of porous fibrillar network consisting of packed and long fibrils with 
approximately 200-300 nm diameter (Figure. 9).  However, the addition of ECM components 
(LAM, FN or VN) changed the structures of the network. For example, Col I matrices alone 
showed heterogeneous fibrillar network in pore size and fiber size (Figure. 9A). The addition of 
LN (25 µg/ml) increased the matrix heterogeneity with some smaller fibrils twisted together to 
form larger fibrils, which appear like aggregates and amorphous regions (Figure. 9C). The 
mixing with FN and VN induced a much denser fiber network with smaller pore sizes (Figure. 
9I). Also, SEM micrographs of seeded scaffolds showed that the cells differentiated in 3D 
cultures were tightly attached to the scaffolds and secreted ECM-like proteins, suggesting the 
suitability of the collagen-ECM scaffold for hESC growth and differentiation  
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3.4.4. Enhancement of DE differentiation in 3D collagen-ECM scaffolds  
To examine whether ECM-collagen scaffolds can improve the DE differentiation from 
hESCs, gene expression profile of DE markers such as Sox17, Foxa2, and CXCR4 were analyzed 
after 4 days of DE differentiation through qRT-RCR assay.  As shown in Figure.10A, the 
mixing of LM or FN in Col I matrices increased DE marker Sox17, Foxa2 and CXCR4 
expression by 103 fold, 7 fold, 19 fold or 65 fold, 24 fold, 28 fold, respectively as compared to 
those detected in 2D DE differentiation. However, the mixing of VN with collagen did not 
improve the DE differentiation, which showed similar expression level as those in 2D DE 
differentiation. Interestingly, the mixing of LM, FN and VN with collagen significantly 
improved the DE differentiation, indicated by the increased gene expression of Sox17 79-fold, 
Foxa2 60-fold and CXCR4 75-fold as compared to those in 2D hESC DE differentiation, 
suggesting that FN, LM, VN may need to work synergistically to maximize the enhancement of 
DE differentiation. We also found the remarkable downregulation of  pluripotency markers, Oct4 
and Nanog in cells differentiated within scaffolds as  compared to those detected in 2D 
differentiation, indicating the 3D cultures could further decrease the pluripotency of hESCs 
during DE commitment than 2D cultures. In addition, the cells differentiated within scaffolds 
expressed a decreased level of ectoderm markers PAX6, Sox3 and mesoderm markers Brachyury 
and N-CAD, suggesting that more cells were differentiated towards DE lineage when they were 
differentiated within scaffolds.  This observation was confirmed by flow cytometric analysis.  As 
shown in Figure. 10B, 10% more SOX17+ cells were detected in hESCs differentiated within 
collagen scaffolds as compared to those differentiated in 2D cell culture plates. More than 90% 
of cells in cell clusters formed within FN-LM-VN-collagen scaffolds were DE cells.  
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Immunofluorescent staining showed that above 95% cells differentiated within FN-LM-
VN-collagen scaffolds expressed Sox17 and Foxa2 simultaneously, while only about 70% cells 
were both positive in cells differentiated in 2D cultures (Figure. 11). Moreover, the DE 
differentiated cells are organized into clusters inside of the scaffolds, resembling the formation 
3D structures.  
 
3.4.5. 3D matrices improve the secretion of ECMs by DE-differentiated cells 
The gene expression level of ECM components produced by DE differentiated cells in 
3D and 2D environments were examined through qRT-PCR assay. Figure. 12 showed that 
differentiated DE cells cultured in 3D scaffolds expressed higher gene expression levels of 
fibronectin 1 (FN), laminin gamma 1 (LM), collagen type IV alpha 1 (Col IV), collagen type III 
alpha 1 (Col III), collagen type I alpha 2 (Col 1α2) than in 2D culture, which imply that the ECM 
secreted by cells in 3D may further improve the DE differentiation of hESCs. However, Col 1α1 
gene expression in 3D cultures was lower than that in 2D cultures. The mechanism underlying 
the increased expression of these ECM proteins in 3D cultures needs to be further investigated.  
Furthermore, we test the collagen IV secretion and its organization in either 3D or 2D 
differentiation through immunohistochemical staining assay (Figure. 13). The addition of LN or 
FN and the mixing of LN, FN, VN to the collagen solution when fabricating the scaffolds led to 
the depositing of more collagen IV to the ECM within the scaffolds (Figure. 13).  In addition, a 
more denser fibrillar structure that was observed in cell clusters formed within scaffolds.   In 2D 
culture, we also observed few col IV expressions around the cells; however, the distribution of 
collagen IV on 2D culture did not display distinct structure and just deposited on the periphery of 
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cells membrane. Because matrigel, which was used to coat cell culture plate before seeding cells, 
contains some collagen IV protein, so the expression of col IV on 2D culture may also probably 
came from Matrigel, not the DE cells secreted. 
 
 
Discussion 
The use of ES cells in combination of with scaffolds holds invaluable promises for 
engineering all kinds of 3D tissues or organs for transplantation. Nevertheless, the understanding 
of knowledge on mechanisms underlying ES cell development and differentiation in a 3D 
environment is crucial to meeting this challenge.  It is widely recognized that ECM plays an 
important role in regulating stem cell differentiation [197]. Here, we designed a novel in vitro 
culture system by utilizing collagen scaffolds combined with ECM proteins to provide a robust 
hESC DE differentiation system, which may further improve the differentiation efficiency and 
maturation of DE lineage cells such as insulin-producing β cells.    
Successful derivation of β-cells from hESC largely depends on the efficient generation of 
DE population. hESCs were able to differentiate into DE by the addition of Activin A but only in 
the presence of low FBS [105]. The possible reason could be FBS contains in insulin-like growth 
factor (IGF) which was known to activate PI3K in hESCs. In our experiments, Activin signaling 
was able to augment DE differentiation when PI3K activity is inhibited. This result was 
consistent with other’s work [107, 109]. Also, there are several critical parameters that influence 
the effect of wortmannin on DE differentiation. Although wortmannin at concentration between 
25 nM and 50 nM works effectively, when wortmannin was used below this level, the efficiency 
of DE formation diminished, presumably because PI3K is not effectively inhibited. Also, when 
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wortmannnin was used a higher concentration (> 50 nM), we saw a concentration-dependent 
increase in cell death consistent with the role for PI3K in cell survival. This suggested that 
different thresholds of PI3K signaling in hESCs are responsible for different cell fate outcomes. 
Here, the hESCs were cultured under collagen-ECM scaffolds, particular in combination 
with adhesive proteins, such as FN, LN and VN. The effect of the ECM proteins on the 
differentiation of hESCs into DE cells was evaluated through the observation of cellular 
morphologic and protein and molecular genes assays. As shown in Figure 1., multicellular 
clusters were formed and expanded in size along with some outgrowth and cluster-cluster 
connection, but not in cells cultured under two-dimensional conditions. Furthermore, 
immunostaining, flow cytometric and gene expression assays revealed that the cells retained 
characteristics of definitive endoderm development.   
We speculate that the ECM may have enhanced the efficiency of cell differentiation in 
several ways. First, there may have some direct signaling from the ECM itself, promoting 
attachment and migration through porous structure. From the bright field and SEM images, the 
results showed the cells were proliferated and migrated to form clusters during the culture period. 
Also, the real time RT-PCR results demonstrated that by adding additional ECM proteins like 
fibronectin, laminin, and vitronectin together in collagen I scaffolds, the DE differentiation 
efficiency was further improved. These findings are consistent with our earlier report that a 
collagen scaffold can be used as an attractive model to differentiating pancreatic β cells.  
In addition, the 3D tissue formation during DE differentiation facilitated by the 3D ECM 
may promote cell-cell signaling that controls the interactions among cells, a clear advantage of 
3D over 2D system. A 3D environment, in which each cell is surrounded by similar cells, may 
reinforce chemical signals that each cell experiences from its neighbors, helping synchronize and 
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promote differentiation of the entire cell population. More than 90% of cells derived from our 3D 
cultures were SOX17 positive. As such, our data indicates that compared to individual ECM 
proteins, ECM protein mixture better promotes cell to cell and cell to ECM interaction resulting 
in improved differentiation.  
In summary, we herein described a new model to culture and differentiate hESCs in 3D 
culture conditions. The combination of scaffolds with ECM molecules, in the presence of 
appropriate soluble signals, results in higher DE differentiation efficiency. This system may 
provide an alternative strategy for generating insulin-producing cells. 
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Chapter 4 
Enhanced Pancreatic β cells Differentiation from Embryonic Stem Cells in 3-D Collagen I-
Matrigel Scaffolds 
4.1. Abstract 
 The success in directed differentiation of human embryonic stem cells (hESCs) into 
insulin-producing β cells raises new hopes for cell-based diabetes therapy. Here we reported a 
highly efficient approach to induce hESCs to differentiate into mature insulin-producing cells in 
a biomimic 3D collagen/Matrigel scaffold. Collagen incorporated with 35% (v/v) Matrigel was 
showed to be the most optimal composition for enhanced DE differentiation as compared to 10% 
(v/v) and 50% (v/v) Matrigel and resulted in 95% SOX17-positive cells. Also, we showed small 
molecular (-)-indolactam V (ILV) promoted the generation of PDX1/HNF6 positive pancreatic 
progenitors when combined with other growth factors. The 3D differentiated pancreatic 
endocrine cells were assembled into tissue-like structure that displayed greater similarities in 
phenotype and gene expression profile to adult human islets. Our results showed that 
approximately 20% insulin positive cells were generated in collagen/Matrigel scaffold as 
compared to 5% in 2D culture, which correspondingly increased four-fold insulin release in 
response to high glucose as compared to 2D hESCs-derived pancreatic cells. Moverover, more 
mature insulin-secreting granules were observed in hESCs-derived pancreatic endocrine cells in 
collagen/Matrigel scaffold than cells in 2D culture. This work clearly demonstrated the 
feasibility of utilizing this novel designed biological 3D scaffold for generating mature clinically 
relevant insulin-producing β cells for treatment of diabetes.  
 
 57 
 
4.2. Introduction 
 Diabetes mellitus has become a global epidemic with striking impacts on patients’ health, 
society and economy. Islet transplantation has been suggested to be a promising therapeutic 
treatment for the treatment of diabetes. Even though some improvement has been made in islet 
transplantation, this therapy was not widely available due to the shortage of donor islet tissue [47] 
and cell loss during islet isolation [198]. The development of unlimited number of pancreatic 
insulin-producing β cells from human embryonic stem cells (hESCs) has emerged as the most 
attractive alternative.  
 hESCs could spontaneously differentiate into insulin-producing cells, but only 1-3% 
insulin-positive cells were generated among differentiated embryonic bodies [103]. In some 
cases, the insulin expression from differentiated embryonic stem cells is due to artifacts of the 
insulin uptake from medium [101, 102, 199].  To address these issues, a stepwise combination of 
different growth factors and small molecules has been developed to generate insulin-producing β 
cells, which mimicking the critical events in vivo pancreatic organogenesis by guiding cells 
through stages of definitive endoderm formation, pancreatic specification, and maturation [104, 
109, 200]. In these reported protocols, cells released insulin and C-peptide, expressed certain 
islet transcription factors. However, these insulin-positive cells most exhibited immature islet 
characteristics. For example,  the insulin-producing cells generated by D’Amour et al’s five 
stage protocol [104] released C-peptide in response to secretagogues, such as potassium chloride 
(KCl), but they were not glucose-responsive and C-peptide content was about 50% lower than in 
human islets. Also, in general the differentiation efficiency of insulin-producing cells was quite 
low and the cells are mostly polyhormonal with a poorly defined phenotype [168, 200]. It has 
also been reported that the hESCs-derived pancreatic progenitors transplanted into athymic nude 
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rats failed to produce substantial number of beta-like cells [201]. Collectively, further efforts are 
needed to not only improve the differentiation efficiency, but also promote maturation of insulin-
producing from hESCs in vitro.  
 The common disadvantage of the most current protocols for generating insulin-producing 
cells from hESCs is using conventional 2D monolayer culture, which lack of support from extra-
cellular matrix (ECM), which plays an important role in cell grow and development. Cell-matrix 
interactions have been shown to improve β-cell survival [90, 177, 202], proliferation [203, 204] 
and insulin secretion [177, 205]. Yashpal et al. work showed that blocking islet-matrix 
interaction by using β1 integrin antibody leads to decrease of insulin gene expression and islet-
cell apoptosis [206]. Collagen gel has been used as a model for culturing stem cells in three-
dimensional (3D) environment, which provides a condition much more similar to native tissue 
ECM than two-dimensional culture dishes [207]. Specially, the collagen gel and surrounding 
medium fluid constitute a soft and flexible fibrous network that supports the rounded 
morphology of cells and allows cells to freely reach out and migrate and from three-dimensional 
structures. However, collagen I alone was not sufficient to provide multiple cues and 
sophisticated geometry and composition that existed in native ECM for synergistically 
enhancement of stem cells differentiation. We therefore augmented a collagen I matrix with 
Matrigel™, a commercially available preparation of basement membrane proteins comprising 
laminin, collagen IV, fibronectin, heparin sulfate proteoglycans and entactin and so on. Oberg-
Welsh, C. et al. have shown that Matrigel significantly enhanced the insulin secretion of fetal 
porcine islet-like cell clusters in vitro [208]. The combination of collagen and Matrigel could 
provide not only physical supports for ESCs development and differentiation, but also the 
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necessary components of ECM. This method has been successfully applied to the tissue 
engineering of cardiac muscle uterus, and kidney [209, 210].  
 Our goal in this work was to develop a scaffold to serve as a platform for robust 
differentiation of insulin-producing cells from hESCs for islet transplantation. We hypothesized 
that the collagen/Matrigel scaffold would support hESCs grow and enhance the differentiation of 
hESCs into mature insulin-producing β cells. To test this hypothesis, we investigated the 
formation of ielet-like insulin-producing cells in 3D culture by using a modified step-wise 
protocol. The maturity of final differentiated cells was evaluated. 
 
4.3. Materials and Methods 
4.3.1. hESCs culture 
Human embryonic stem cells (hESCs), H9 (WiCell Research Institute, Madison, MI), 
ware cultured on Matrigel (BD Biosciences, Bedford, MA)--coated cell culture plates in 
mTeSR®1 medium (StemCell Technologies Inc., Vancouver, BC, Canada). A solution of 
1mg/ml dispase in DMEM/F12 medium was used to passage cells every 3-5 days. The cultures 
were incubated at 37°C in the atmosphere supplemented with 5% CO2, with the cell culture 
medium changed daily. 
 
4.3.2. Collagen/Matrigel scaffolds preparation 
 Collagen  type I gels were prepared at 1.5 mg/ml concentration under sterile condition by 
diluting the rat tail tendon-derived collagen I solution (BD Biosciences, Bedford, MA) with 10× 
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phosphate buffered saline (Mediatech, Inc., Manassas, VA),  cell culture grade DI water (Thermo 
Fisher Scientific Inc., Waltham, MA). The pH of the mixture was neutralized immediately to 7.4 
using 1 N NaOH. To create combinational collagen/Matirgel scaffolds, growth factor-reduced 
Matrigel (BD Biosciences, Bedford, MA), a solubilized basement membrane preparation, was 
incorporated in collagen I solution at 10%, 35% or 50% by volume of collagen solution. The 
solution were then neutralized to pH 7.4, and added into 48-well plates and incubated at 37 °C 
for 1 hour to induce gelation. No cross-linking agent was used. 
 
4.3.3. hESCs Pancreatic differentiation of on Matrigel and in Collagen/Matrigel scaffolds 
 H9 cells were treated with the ROCK inhibitor, Y-27632, in cell culture medium for 2 
hours before dissociating. After incubating with AccutaseTM (StemCell Technologies Inc.), cell 
suspension was obtained after pelleted and resuspended in addition of mTeSR®1 medium. For 
3D cultures, 10% volume of cells suspension (1.2×106 cells) was mixed with each 0.5 ml 
collagen I solution with or without different concentration of Matrigel. The cell-matrices solution 
was added to a 24-well plates (BD Biosciences, San Jose, CA), resulting in an initial radius of 8 
mm and a thickness of 2.5 mm. The 3D constructs were placed in incubator at 37 °C for 1 hour 
for gelation. Once the gels had set, 0.5 ml of cell media was added to the top of the gels and the 
matrix was returned to the incubator. Moreover, two-dimensional culture was prepared for 
comparison by culture H9 cells directly on the top of Matrigel-coated culture plate. The cells 
were allowed to grow in scaffold or on Matrigel in mTeSR medium supplemented with 10 µM 
Y-27632 for 24 hours for attachment and proliferation. A modified step-wise protocol, which is 
similar to Zhang et al’s approach but with some modifications, was carried out for hESCs 
pancreatic differentiation (Figure 14). 
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4.3.4. Scanning electron microscopy 
 For SEM, 3D matrices were washed with PBS to remove proteins in the culture medium 
or other impurities and then fixed overnight in 2.5% (v/v) glutaraldehyde (Electron Microscopy 
Sciences, Hatfield, PA) at room temperature. After fixation, the matrices were thoroughly 
washed off the fixative with distilled water. Then, samples were snap frozen in liquid nitrogen (-
196°C) and broken with cold forceps. A fragment of the frozen gel was transferred into a 
chamber of freeze dryer for low-temperature (-100°C) high-vacuum dehydration. Dried samples 
were mounted on SEM sample stages using carbon tape and sputter-coated with gold-plutonium 
(palladium) alloy (Pd/Au) to a thickness of 6 nm under vacuum using a Palaron SC7620 sputter 
coater (Watford, UK). Samples were then analyzed by Jeol Field Emission SEM (JSM-6335F, 
JEOL USA, Peabody, MA) using a low-vacuum mode (0.75 Torr), at 10kV accelerating voltage 
and 7.7mm working distance. 
 
4.3.5. Quantitative real-time polymerase chain reaction 
Cell-scaffold constructs were mechanically homogenized with a Tissue-Tearor (BioSpec 
Products, Bartlesville, OK) while cells cultured on Matrigel-coated tissue culture plate were 
harvested with a cell scraper. Total RNA was extracted from cultured cells using an RNeasy Plus 
Mini kit (Qiagen, Valencia, CA) after Prior to reverse transcription (RT), RNA samples were 
digested with DNase I to remove contaminating genomic DNA. Reverse transcription was 
performed with 1 µg of total RNA using High Capacity cDNA Reverse Transcription Kit 
(Invitrogen) followed by the manufacture’s instruction. Real-time quantitative PCR was carried 
out using the Power SYBR Green PCR master mix (Applied Biosystems) and was performed on 
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the Realplex Real-Time PCR system (Eppendorf, Realplex4 model). Initial enzyme activation 
was performed at 95 °C for 15 min, followed by 40 cycles of denaturation at 95 °C for 15 s, and 
primer annealing/extension at 60 °C for 1 min. Melting curve analysis was performed at 95 °C 
for 1 min, 60 °C for 30 s and 95 °C for 30 s. Primer’s sequences are given in table 1. The 
expression levels of target genes were normalized against endogenous control β-actin. All 
samples were analyzed in triplicates. 
 
4.3.6. live/dead cell staining in 3D collagen/Matrigel scaffolds 
The cell viability within scaffolds was determined using live/dead cell double staining kit 
(Sigma-Aldrich, Saint Louis, MO). Cell-scaffold 3D constructs were incubated with 200 µl 
live/dead staining solution at 37oC for 15min by following the manufacture’s instruction. The 
excess dye solution was removed and 0.5 ml of PBS was added on the top of the gel. Excess 
buffer was subsequently removed in order to stabilize the cell containing scaffolds sample for 
imaging. Samples were examined by using the Olympus upright microscope (IX71, Tokyo, 
Japan) equipped with a supersensitive CCD camera (mode number ROLERA-XR, Surrey, BC, 
Canada) controlled by an imaging analysis software Slidebook (Intelligent Imaging Innovations, 
Inc., Denver, CO). 
 
4.3.7. Immunofluorescence staining 
 Scaffold-embedded cells were fixed in 4% paraformaldehyde for 15 min and washed 3 
times with PBS. Permeabilization was performed with 0.1 Trixton X-100 for 5 min. 
Cryosectioning of scaffolds was performed as described elsewhere [196]. Briefly, Scaffold-cell 
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constructs were fixed in 10% neutral-buffered formalin solution (NBF) for 3 hours.  After 
overnight infiltration with a series of 20% sucrose and sucrose/OCT® solution, the scaffolds 
were placed in a peel-away mold (VWR, south Plainfield, NJ) in tissue freezing medium (Tissue-
Tek OCT Compound, Sakura-Fintek). All the molds were then placed into the MICROM 
cryostat (Richard-Allan Scientific) chamber and the samples were allowed to freeze at -20oC for 
at least 30min.  Routine frozen sectioning was performed by collecting 8-µm sections onto 
positively charged slides. The scaffold sections were either collected or air dried for a minimum 
of 30min. Before staining, sections were hydrated in PBS for 10min and then permeabilization 
was performed with 0.1 Trixton X-100 for 5 min. then incubated in blocking buffer (PBS 
containing 5 % normal goat serum, 0.3 % Triton X-100) for 1 h and thereafter nonspecific 
antibody binding was blocked by 10% normal serum from the species in which the secondary 
antibodies were raised. Cells were incubated with primary antibodies overnight at 4 °C followed 
by secondary antibody incubation for 1 hour at room temperature. To stain 2D cultures, cells 
seeded on Matrigel-coated plates were fixed with 4 % paraformaldehyde (Sigma). After treated 
in blocking buffer to inhibit unspecific labeling (45 min at room temperature), cells were labeled 
with primary and secondary antibodies as described above. DAPI (Research Organics) were used 
to counterstain the nucleus. Images were captured under an inverted fluorescence microscope 
(Olympus, IX71, Japan). The primary antibody and secondary antibody are described in Table 1.  
 
4.3.8. Flow cytometry  
For 3D culture, hydrogels were digested with 2mg/ml collagenase solution (Life 
Technologies) for 30min at 37oC. After centrifugation at 300x g for 5min and aspiration of 
supernatant, the cells were then treated with 0.25% typsin with EDTA (sigma) to further digest 
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the cells into single cell suspension. Cells were filtered through 70mm cell strainer (BD 
FalconTM) to removes the clumps. For 2D culture, cells were dissociated using AccutaseTM cell 
detachment solution (Millipore) for 5 min followed by removal of trypsin by centrifugation. 
Cells were then fixed with 4% paraformaldehyde and permeabilized with ice-cold methanol. 
Cells were labeled with PE mouse anti-human Sox17 (BD Biosciences) at 5 µl per 1 × 106 cells 
or mouse anti-human Insulin (Cell signaling Technology, Inc.) for 45min at room temperature in 
the dark. Cells labeled with PE mouse IgG1ĸ was used as isotype control. Cells were washed 
three time and resuspended in PBS with 10% inactivated FBS and 0.09% sodium azide. Samples 
were acquired on a BD fluorescence activated cell sorter (FACS) Calibur flow cytometer 
(Becton-Dickinson Biosciences, Franklin Lakes, NJ) and data analyzed using Bection-Dickinson 
CellQuest software (BD Biosciences).  
 
4.3.9. Glucose stimulated insulin secretion assay  
 To determine if cells at the end of differentiation were capable of glucose-stimulated 
insulin release (GSIR), cells in 2D and 3D culture were washed three times with Krebs-Ringer 
buffer containing 0.1% BSA and 10mM HEPES and first incubated with Krebs-Ringer buffer 
free of glucose for 60 min at 37°C. Afterward, every dish was exposed to Krebs-Ringer buffer 
containing 5.5 mM, 15 mM or 25 mM glucose for 90 min at 37°C. Supernatant were then 
collected and insulin level were measured by using an Insulin ELISA kit. The amounts of insulin 
secretion were normalized by measuring total intracellular protein using BCA™ protein assay kit 
(PIERCE). Each experiment was triplicated performance. 
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4.3.10. Transmission electron microscopy (TEM) 
 2D cells and 3D matrices were fixed in 3% glutaraldehyde in 0.1 M cacodylate buffere 
(pH 7.4) for 2 hours at room temperature. After rinsing in 0.05 M cacodylate buffer, samples 
were post-fix in 1% osmium tetroxide for 2 hours and rinsed with distilled water. After prestain 
overnight in 0.5% uranyl acetate at 4 °C, samples were dehydrated through a graded ethanol 
series to 100%, rinsed in propylene oxide and embedded in Spurr’s epoxy. 80 nm thick sections 
were cut on a MT2-B ultramicrotome and stained in 2% uranyl acetateand lead citrate. Samples 
were examined using a Philips EM 410LS TEM operated at 80 kV. 
 
4.3.11. Statistical analysis 
All experiments were carried out at least in triplicate. Unless otherwise indicated in the 
text, all analytical measurements were repeated three times. All data were expressed as means ± 
standard deviations. Statistical analysis was performed with Student’s t-test, with p<0.05 
considered as statistically significant. 
 
4.4. Results  
4.4.1 Scaffold morphology 
The incorporation of various concentration of Matrigel in collagen scaffold affects the 
microstructural features. SEM images of these collagen/Matrigel scaffolds exhibited well-
defined, interconnected pore structures (Figure 15). In these constructs, 10% Matrigel constructs 
appeared less interconnected and less uniformly distributed. As the percentage of Matrigel 
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increased to 35% and 50%, the relative homogeneity of these scaffold morphological features 
can be appreciated, with more tightly packed fibrils and smaller pores. It was evident that the 
increases of Matrigel concentration gave rise to a subststaintial decrease of both void and 
interconnect size.  
 
4.4.2. Effect of Matrigel on the hESCs definitive endoderm differentiation 
 To examine the effect of Matrigel on the efficiency of hESCs differentiation into 
pancreatic cells, hES cells were seeded into 1.5 mg/ml collagen gel incorporated with 10%, 35% 
or 50% (v/v) of Matrigel respectively. DE differentiation was implemented for 4 days and cells 
were harvested at the end of this stage for analyzing the expression of DE marker genes. As 
shown in Figure 16A, the incorporation of Matrigel in collagen gel significantly improved the 
expression level of DE genes such as Sox17, Foxa2 and CXCR4 compared to hESCs 
differentiated on 2D Matrigel substance. Among the three different scaffolds, 35% Matrigel 
showed the best effect on the enhancement of DE differentiation, which improved Sox17, Foxa2, 
CXCR4 expression by 35-fold, 22-fold, 10-fold respectively, which was 2-3 fold increases 
compared to cells differentiated 10% or 50% (v/v) Matrigel constructs. Corresponding to the 
qRT-PCR results, flow cytometry was used to analyze the Sox17 positive population in the 
differentiating cells on day 4. As showed in Figure 16B, 95% of cells are identified Sox17+ in 35% 
Matrigel as compared to 73% Sox17+ in 10% Matrigel and 85% Sox17+ in 50% Matrigel. This 
was in good agreement with the gene expression profile.  
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4.4.3. The morphological and viability analysis of hESCs pancreatic differentiation in 
collagen/Matrigel scaffolds 
 To compare the morphological changes of differentiating cells cultured under two- and 
three-dimensional conditions, undifferentiating single cells were seeded on Matrigel-coated cell 
culture plates or in 35% Matrigel/Collagen scaffolds and cell morphology was observed by 
phase-contrast microscopy at day 4 and day 10. Cells under 2D and 3D culture all proliferated 
rapidly, however, the morphology of cells differed greatly (Figure 17).  In monolayer culture, the 
cells lost classical hESCs morphology and present a confluent monolayer with uniform 
morphology of flat, polygonal shape on day 4 of pancreatic differentiation, which showed overt 
differentiation. Upon the differentiation process, the cell cultures were densely packed and 
formed some tightly packed aggregates on day 10 of differentiation.  In the collagen/Matrigel gel 
culture system, a number of newly formed cell clusters appeared by cell proliferation, 
homogenously distributed as shown by phase contrast microscopy. The size of the clusters grew 
over time, resulting in spherical shapes with densely packed cells at day 10. Also, the outgrowth 
of cells from the periphery of most clusters was observed and cells formed tissue-like structures, 
indicating the initiating of hESCs differentiation. The viability of cells in 3D collagen/Matigel 
culture was determined by calcein-AM/PI live/dead cell staining. Almost all the cells in 3D 
culture were viable, and the viability remained high (approximate 98% viable cells) even after 10 
days of differentiation (Figure 17F). These results suggested that the 3D collagen/Matrigel 
culture system developed in this study provided a suitable cell housing microenvironment for 
hESCs proliferation and differentiation. 
 
4.4.4. ILV treatment promoted the generation of pancreatic progenitor cells  
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 In order to promote the commitment of hESCs differentiation into PDX1-expression 
progenitor cells, a small molecular (-)-indolactam V (ILV) was combined with growth factors 
reported to be involved in pancreatic development, including retinoic acid (RA), FGF7 and 
noggin. ILV was found to be able to specifically induce pancreatic progenitors from definitive 
endoderm. We found that the addition of ILV at stage II resulted in increase of gene expression 
of pancreatic progenitor markers including PDX1, SOX9, and HNF6 by 20-fold, 16-fold, and 63 
fold respectively, on day 8 of pancreatic differentiation (Figure 18B). Consistent with the gene 
expression analysis, immunostaining revealed that larger population of cells were stained both 
PDX1 and HNF6 positive in the culture that treated with ILV compared to non-ILV treatment 
control, which indicated the importance role of ILV signaling in pancreatic progenitor generation. 
Specifically, the 3D structure of pancreatic progenitors was observed in 3D collagen/Matrigel 
culture system after 4 days of ILV treatment along with other growth factors for pancreatic 
progenitor differentiation.  
 
4.4.5. Immunohistochemical characterization of hESCs-drived insulin-producing cells in 
collagen/Matrigel scaffold 
To obtain insulin-producing cells in vitro, the stage 3 EP cells were incubated with 
exendin-4, nicotinamide, BMP4 and bFGF for 7 days. As shown in Figure 19, at the end of 
differentiation in this experiment, insulin-producing cells were observed, and these cells tent to 
be organized into a 3D islet-like structure.  Also, the insulin-producing cells co-produced C-
peptide, a by-product from proinsulin process, indicating the de novo endogenous insulin 
production, as opposed to uptake from the culture medium. As an essential regulation of 
pancreatic development, the expression of PDX1 was also observed, with co-expression of 
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NKX6.1 and NGN3, which confirmed their pancreatic β cell characteristics. Within the 3D 
cellular architect, the endocrine hormones that secreted from pancreatic α, δ and PP cells-
glucagon, somatostatin and pancreatic polypeptide were detected in a small number of cells, 
which is consistent with the hormone expression pattern of mature islets. These results indicate 
that hESCs can be differentiated into insulin-producing cells through a four-stage protocol and 
organized into islet-like 3D structure in the developed collagen/Matrigel scaffold. 
 
4.4.6. Gene expression profile of hESCs-derived insulin-producing cells in 2D and 3D  
 The expression pattern of pancreatic markers in 2D and 3D culture throughout 
differentiation was monitored by quantitative real-time PCR. As illustrated in Figure 20, the 
expression peak of Sox17 was observed at the end of stage I and the expression level in cells 
cultured in collagen/Matrigel 3D culture was enhanced by 14 folds compared to cells in 2D, 
indicating the enhancement of definitive endoderm differentiation in 3D culture. The expression 
of PDX1 and NGN3 emerged at stage II and reached the peak at the end of stage III, suggesting 
pancreatic specialization. The data showed that the enhancement of PDX1 and NGN3 expression 
in collagen/Matrigel scaffold compared to 2D culture persisted throughout the differentiation 
process.   In addition, we observed enhanced Insulin gene expression in Collagen/Matrigel 
scaffold at each time point and reached the peak at the end of stage IV differentiation, which 
resulted in 5 fold increase as compared to cells cultured in 2D.  Glut2 is a glucose transporter 
found in the cell membrane of mature β-cells and is not only an important indicator of β-cell 
maturity but also is required for glucose-induced insulin release. Glut2 gene expression level was 
enhanced in 3D culture at each time point or compared to 2D culture values. Additionally, MafA 
gene expression is a hallmark of fully differentiated pancreatic endocrine cells.  Our data showed 
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that MafA gene was upregulated along with the process of pancreatic differentiation process 
increased 5 folds compared to 2D culture at the end of differentiation. 
 
4.4.7. Insulin secretion in 2D and 3D culture 
 The biological function of hESCs-derived insulin-producing cells β cells in 2D and 3D 
culture were determined by insulin secretion upon glucose challenges (Figure 21A). A nearly 
4.5-fold and 7 fold increase in insulin secretion from 3D induced cells were observed when cells 
were incubated in 15 mM and 25 mM high glucose-containing medium, in comparison with 
buffer containing lower glucose concentration (5.5 mM). Conversely, only 2.8-fold and 3.7 fold 
increase in insulin secretion was detected in 2D induced cells when they were incubated in 15 
mM and 25 mM high glucose-containing medium. Approximately, 44 ± 4.9 µIU insulin/mg 
cellular proteins were secreted from 3D-induced cells in high glucose (25 mM)-containing 
medium, whereas only 10.8 ± 3.2 µIU insulin/mg cellular proteins from 2D-induced cells. This 
represents an approximate four-fold increase in 3D-induced cells compared to 2D-induced cells 
when cells challenged with high glucose concentration. These results indicate that 3D induced-
insulin producing cells are more sensitive to a glucose challenge due to their improved maturity. 
Furthermore, we analyzed the percentage of insulin+ cells by using flow cytometry. After 
approximate 21 days of pancreatic induction, the insulin-positive cells were reached 
approximately 20% in 3D collagen/Matrigel culture, compared to 5% in 2D. It suggested 3D 
culture not only promote the maturity of hESCs-induced β cells, but also enhanced the 
production of insulin-section cells in a higher population. 
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4.4.8. Ultrastructural characteristics of hESC-derived pancreatic cells 
 We used transmission electron microscopy to determine whether the hESCs-derived cells 
formed mature secretory granules. The typical mature insulin granules were observed in 2D and 
3D induced cells (Figure 22), which is characterized by round electron-dense crystalline core 
surrounded with the distinctive large, clear halo. The inner crystalline core of insulin granule is 
less electron opaque in mature β cells than those found in glucagon-containing and somatostatin-
containing α- and δ- cells, which confirmed the generation of insulin-producing β cells. The 
granule number was approximately 12 times fewer in 2D-induced cells than in 3D-induced cells 
as counted from 5 individual cells from each sample.   
 
4.5. Discussion 
 Current protocols for stem cell differentiation mainly rely on mimicking the sequence of 
signaling events that underlies the differentiation of tissues in embryological development. Apart 
from specific soluble growth factors for lineage specific differentiation, the importance role of 
ECM on stem cell differentiation is greatly ignored. In this study, we established a new model 
for hESCs differentiation and we demonstrated that more mature insulin-producing cells can be 
generated from hESCs with higher efficiency in the designed three-dimensional culture system.  
Collagen I hydrogel is mechanical robust and easy to handle, which is of practical 
importance when translate their use as engineered tissues in the clinic. In addition, the main 
ECM of mature human islets has most often been reported to be composed of laminin and 
collagen IV [185]. Therefore, it is possible that the addition of Matrigel allows hESCs to 
preferentially attach to the properties of their native environment and perform the differentiation 
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close to in vivo development in the composite matrices that developed in this study. Recent 
studies in stem cell biology revealed that when exposed to the intrinsic properties of the 
extracellular matrix, such as matrix structure, elasticity, and composition, stem cells can 
differentiate into various lineage of mature tissue cells [149]. Incorporation of Matrigel in 
collagen gel can cause distinct changes in the constructs morphologies and mechanical properties 
Thus, in this study; we incorporated Matrigel at different ratio (10% v/v, 35% v/v or 50% v/v) in 
collagen gel and tried to figure out the preferred condition for pancreatic differentiation. The 
changes in fibrillar structure were confirmed by SEM. At low Matrigel concentration (10% v/v), 
the matrix structure was uniform with a fine fiber structure, whereas at higher percentages of 
Matrigel, larger fibrils appeared with uniform pore size. Also, the mechanical properties differed 
in various collagen/Matrigel scaffolds has been reported [211]. The higher concentration of 
Matrigel incorporated in collagen gel resulted in increased Young’s moduli of the various 
collagen-Matrigel compositions[211]. The differences in architectural and mechanical properties 
of collagen/Matrigel scaffolds were related to stem cell differentiation efficiency. Our data 
showed that 35% Matrigel gave rise to the highest expression of definitive endoderm gene, such 
as Sox17, Foxa2 and CXCR4. The efficient generation of DE cells would facilitate the following 
differentiation step. Thus, the collagen gel incorporated with 35% Matrigel was used in other 
experiments.  
Another factor that may contribute to expansion and maturation of insulin-producing 
cells in 3D culture is the use of growth factors and small molecules. Activin A has been used to 
induce DE cells in most reports. However, recently study by Mclean et al. showed that Activin A 
efficiently specified DE differentiation from hESCs only when phosphatidylinositol 3-kinase 
(PI3K) signaling is suppressed [107].  In this study, wortmannin, a PI3K inhibitor, was used for 
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DE induction and it showed 95% of cells in collagen/Matrigel (35% v/v) scaffolds were Sox17 
positive. For differentiation of DE cells into pancreatic progenitors, the combinational use of 
Noggin, an inhibitor of bone morphogenetic protein (BMP) signaling, retinoic acid, and 
fibroblast growth factor 7 (FGF7 or KGF), which were  reported to induce pancreatic progenitor 
cells generation in our studies [106, 212-214], was applied in our protocol.  In addition, by using 
high-content screen in a chemical library of 5,000 compounds, (-)-indolactam (ILV) was 
identified to induce PDX1-positive pancreatic progenitor cells at high efficiency [215].  Here, we 
included small molecule ILV in the growth factor regimen and found out that with the addition 
of ILV, the pancreatic progenitor markers PDX1, HNF6 and Sox17 were increased dramatically 
compared to cells treated without ILV. The induction of insulin-producing cells was 
characterized at the final stage. As revealed by immunohistochemical staining, the cluster formed 
in 3D culture consist as lease three types of cells, including insulin-producing β cells, glucagon-
secreting α cells and somatostatin-secreting δ cells, suggesting the expression pattern of mature 
islets.  Moreover, the co-expression of Insulin, C-peptide, PDX1 and NKX6-1 was observed in 
the induced insulin-producing cells in 3D culture, which is considered to be a specific functional 
characteristic of mature β cells [216]. The quantitative PCR-based gene expression profiling 
demonstrated that β-cell specific transcription factors including PDX1, NKX6-1, Insulin and 
Glut2 were significantly increased in the 3D culture and presented a closer gene expression 
pattern to human pancreas development. Furthermore, the maturation phenotype of insulin-
producing was confirmed. For example, the 3D-induced cells can secrete insulin in response to 
glucose stimulation in a more sensitive manner, and the insulin-positive cells comprised about 20% 
of population at the final stage. Furthermore, the insulin-containing granules were detected as a 
symbol of mature β cells.     
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To summarize, in this work we established a novel 3D model to induce hESCs 
differentiate into mature insulin-producing cells that demonstrated more close phenotype and 
gene expression profile to adult human islets. We believe this presented strategy would not only 
provide an efficient method to use hESCs for clinical-relevant application, but also facilitate the 
future study of the mechanism of human pancreatic specialization and maturation in vitro.   
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Chapter 5 
Conclusion and Future Directions 
 In this work, we have established a novel 3D culture system by using nature ECM 
proteins for pancreatic lineage differentiation from hESCs. We believe the data presented in this 
study offered direct evidence supporting the hypothesis that 3D pancreatic differentiation of 
hESCs may represent a valuable technique for generating clinically relevant β cells in vitro. 
These work provided a proof-of-concept study and this method can be transformed to generate 
other lineage specific tissue from ESCs such as hepatocyte and neural cells.  
 The main goal of directing the differentiation of hESCs to β cells is to provide a new 
source of β cells for transplantation therapy. Due to the interesting findings, in order to further 
characterize the maturity of hESCs-induced insulin-producing cells, our future research may lead 
to perform an animal study to further test their ability to maintain blood glucose levels following 
transplantation. hESCs-derived β cells can be transplanted into mouse kidney capsule, and 
function of β cells can be determined by the insulin and glucose concentrations in serum after 
challenging with high glucose. A rapid glucose-responsive insulin release following 
transplantation is highly desired. Creating functional, adult-like β cells in vitro may require 
further understanding of β cell metabolism, the role of islet structure, the pathways or molecules 
involved in 3D niches for pancreatic specification. 
 The development of microscale techninologies offers powerful tools for stem cell study 
and tissue engineering [217]. Scaffold can be fabricated at microscale and nanoscale by the use 
of 3D printing, microsyringe deposition, and electronspinning of nanofibers. These techniques 
allow control of cellular microenvironment in vitro and provide templates for cell aggregate 
formation or perform high-throughput assays. We anticipate that the use high-throughput 
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screening methodologies will contribute to the design of new 3D scaffolds for the expansion and 
lineage-specific differentiation of hESCs. In addition, understanding other limitations of 3D stem 
cell culture may provide guidance for more efficient generation of lineage specific cells. For 
example, vascularization is the capstone in large-scale tissue-engineering application [218]. 
Recent findings suggested that co-culture β cells with microvascular endothelial cells help 
maturation of hESCs differentiation into β cells [219]. Therefore, development of a 3D patterned 
co-culture system in regulating various aspects of cellular microenvironment would be an 
imperative direction for complete maturation of pancreatic β cells generated from human 
pluripotent stem cells. 
 Reproducibility of results across hESCs line is of critical importance for stem cell 
research. Recently, much attention have been given to the description and explanation of 
differences between various hESCs lines [220]. These differences result in large variations in 
propensity of differentiation between cell lines. The data obtained in this study on based on H9 
cell line acquired from Wicell. Although H9 cell line have been widely used in hESCs 
differentiation, the adaptation of this technique in other pluripotent stem cell lines may be 
necessary.  
 
 
 
 
 
 
 
 
 77 
 
Table 1. List of PCR primers 
Gene Sequence 
Product 
(bp) 
Annealing 
temperature (°C) 
SOX17 
5’-GGCGCAGCAGAATCCAGA-3’ 
5’- CCACGACTTGCCCAGCAT-3’ 
102 61  
FOXA2 
5’-GGGAGCGGTGAAGATGGA-3’ 
5’-TCATGTTGCTCACGGAGGAGTA-3’ 
82 bp 60  
CXCR4 
5’-CACCGCATCTGGAGAACCA-3’ 
5’-GCCCATTTCCTCGGTGTAGTT-3’ 
86 bp 62  
OCT4 
5’-TGGGCTCGAGAAGGATGTG-3’ 
5’-GCATAGTCGCTGCTTGATCG-3’ 
92 bp 62  
PAX6 
5’- TCTCCTCCATCAACCGAGTC-3’ 
5’- GAGCCACTATGGGGAGTGAG-3’ 
151 bp 60  
N-CAD 
5’-CCCACACCCTGGAGACATTG-3’ 
5’-GCCGCTTTAAGGCCCTCA-3’ 
96 bp 60  
BRACH 
5’-TGCTTCCCTGAGACCCAGTT-3’ 
5’-GATCACTTCTTTCCTTTGCAGTT-3’ 
112 bp 61  
SOX3 
5’-CCCAGCCTACAAAGGTGAA-3’ 
5’-CCCAGCCTACAAAGGTGAAA-3’ 
102 bp 60  
FN1 
5’- CCCATCAGCAGGAACACCTT-3’ 
5’- GGCTCACTGCAAAGACTTTGAA-3’ 
82 bp 60  
LAMC1 
5’-TGGGCATTCTTCTGTCTGTACAA-3’ 
5’- GCCACCCATCCTCATCAATC-3’ 
86 bp 60  
Col4A1 
5’-ACTCTTTTGTGATGCACACCA-3’ 
5-AAGCTGTAAGCGTTTGCGTA-3’ 
151 bp 60  
COL3A1 
5’-AACACGCAAGGCTGTGAGACT-3’ 
5’-GCCAACGTCCACACCAAATT-3’ 
88 bp 60  
COL1A1 
5’-GAACGCGTGTCATCCCTTGT-3’ 
5’- GAACGAGGTAGTCTTTCAGCAACA-3’ 
91 bp 62  
COL1A2 
5’-AAGGTCATGCTGGTCTTGCT-3’ 
5’-GACCCTGTTCACCTTTTCCA-3’ 
115 bp 60  
SOX9 
5’- AGACCTTTGGGCTGCCTTAT-3’ 
5’- ACTTGTAATCCGGGTGGTCCTT-3’ 
121 bp 60  
HNF6 
5’- TGTGGAAGTGGCTGCAGGA-3’ 
5’- TGTGAAGACCAACCTGGGCT-3’ 
131 bp 60  
PDX1 
5’- AAGTCTACCAAAGCTCACGCG-3’ 
5’- GTAGGCGCCGCCTGC-3’ 
199 bp 60  
NGN3 
5’-CCCTCTACTCCCCAGTCTCC-3’ 
5’-CCTTACCCTTAGCACCCACA-3’ 
114 bp 62  
INSULIN 
5’-GCAGCCTTTGTGAACCAACAC-3’ 
5’-CCCCGCACACTAGGTAGAGA-3’ 
147 bp 62  
MAFA 
5’- CTTCAGCAAGGAGGAGGTCATC -3’ 
5’- CTCGTATTTCTCCTTGTACAGGTCC -3’ 
208 bp 62  
GLUT2 
5’- GCTACCGACAGCCTATTCTA-3’ 
5- CAAGTCCCACTGACATGAAG-3’ 
267 bp 62  
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Table 2. List of Antibodies used in immunocytochemisty and immunohistochemistry 
Antibodies Host Dilution or 
Concentration 
Producer 
Anti-Sox17 Mouse 1:50  R&D Systems 
Anti-Foxa2 Rabbit 1:1000 Abcam 
Anti-Pdx1 Rabbit 1:2000 Abcam 
Anti-Collagen IV Rabbit 1:200  Abcam 
Anti-HNF-6 Mouse 1:200 Santa Cruz Biotechnology, Inc. 
Anti-Nkx2.2 Mouse 2 µg/ml 
Developmental Studies 
Hybridoma Bank 
Anti-Ngn3 Mouse 2.5 µg/ml 
Developmental Studies 
Hybridoma Bank 
Anti-Nkx6.1 Mouse 3 µg/ml 
Developmental Studies 
Hybridoma Bank 
Anti-Insulin Rabbit 1:400 
Cell Signaling Technology, 
Inc. 
Anti-Glucagon Mouse 1:4000  Millipore 
Anti-C-Peptide Mouse 1:100  Millipore 
Anti-Somatosatatin Rat 1:100  Millipore 
Anti-Pancreatic polypeptide Mouse 1:50  R&D Systems 
TRITC-conjugated anti-
rabbit IgG 
Donkey 1:100  Jackson ImmunoResearch 
Alexa Fluor®-conjugated 
anti-rat IgG 
Donkey 1:500  Jackson ImmunoResearch 
DyLight™ 488-conjugated 
anti-mouse IgG 
Goat 1:500  Thermo Scientific 
PE anti-human Sox17 Mouse 1 ug/ml BD Biosciences 
PE IgG1 ĸ isotype control Mouse 1 ug/ml BD Biosciences 
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1. Morphological changes and expression of pluripotent markers of hESCs before 
differentiation. (A-F) Phase-contrast microscopy images of hESCs cultured on MEF feeder 
layers (A-C) or MatrigelTM (D-F). hESCs proliferated from day 2 (A, D), day 3 (B, E) to day 4 (C, 
F). (G-I) Immunocytochemical analysis of pluripotency in H9 hESCs. Cells were stained with 
antibodies against pluripotency marker proteins SOX2 (G), SSEA4 (H), and TRA-1-60 (I) after 
five passages. Cells were also labeled with diaminophenylindole (DAPI) in order to localize the 
nucleus. Stained cells were observed under a fluorescence microscope (Olympus IX 71) 
equipped with a CCD camera. Scar bar (A-C, G-I) 50 µm, (D-F) 300 µm. 
  
(I) (G) 
(A) (B) (C) 
(D) (F) (E) 
(H) (I) 
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Figure. 2. Scanning electron microscopy (SEM) images of the collagen I scaffold. (A) 
Micrographic structure of 1.5 mg/ml collagen I scaffold. (B) hESCs integrated in collagen 
scaffold. Scale bar: 2µm. 
  
(A) (B) 
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Figure. 3. Morphological and viability analysis of hESCs-derived definitive endoderm in 3D 
collagen cultures. hESCs were seeded into a 3D collagen scaffold (1.5mg/ml) as single cells (A, 
B, E, F) or cell clusters (C, D, G, H) in a 24-well plate (2.5×106 cells/ml). A-D: Bright field 
images of hESCs on day 2 (A, C) and day 4 (B, D) of DE differentiation in 3D cultures. E-H: 
hESCs proliferated and maintained a high viability on day 2 (E, G) and day 4 (F, H) as 
determined by live/dead cell staining. Scale bar: 30 µm. 
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Figure. 4. hESCs proliferation in 3D collagen scaffold. hESCs were seeded in collagen scaffold 
as single cells or cell clusters and time course of cell proliferation was performed by Alamarblue 
assay from day 0 to day 5. Fluorescence intensity was detected at excitation wavelength of 570 
nm and fluorescence emission at 590 nm.  Data were the measurements in triplicate experiments 
at indicated time intervals.  
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Figure. 5. Quantitative PCR analysis of DE marker genes and other germ layer marker genes of 
hESCs-induced DE cells after 4 day of differentiation by using single cells inoculation method or 
cell clusters inoculation method. Undifferentiated hESCs were served as control and the mRNA 
levels were normalized to β-actin 
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Figure. 6. Comparison of DE differentiation efficiency by culture hESCs in DE differentiation 
medium A (Activin A and Wnt3a) or medium B (Activin A and wortmannin). (A) Quantitative 
PCR analysis of DE and three germ layers marker genes expression of hESCs-induced cells on 
day 1, day2 and day4 of DE differentiation. Expression levels were normalized to β actin. (B) 
Flow cytometric analysis of SOX17 positive cells in hESCs-induced cells on day 4. (C) 
Immunofluorescence staining of SOX17 (red), FOXA2 (green) in hESCs-induced cells on day 4.  
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Figure. 7. Bright field microscopy images of hESCs-induced cells in 2D and 3D ECM scaffolds. 
hESCs were induced into DE in 2D (A and B),  type I collagen scaffolds (Col I, C and D), and 
collagen along with laminin (LM, E and F), fibronectin (FN, G and H), vitronectin (VN, I and J) 
or mixture of ECM proteins (Mix, K and L). Morphologies were observed on day 2 (left panel) 
and day 4 (right panel) of DE differentiation. Scale bar (A-B) 200 µm, (C-L) 100 µm. 
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Figure. 8. The viability of hESCs-induced DE cells in 3D ECM scaffolds. hESCs were cultured 
into type I collagen scaffolds (Col I, A and B), and collagen I along with laminin (LM, C and D), 
fibronectin (FN, E and F), vitronectin (VN, G and H) or mixture of ECM proteins (Mix, I and J) 
in DE differentiation medium for 4 days. Live/dead staining were performed on day 2 (left panel) 
and day 4 (right panel) of DE differentiation. Images were taken using an inverted fluorescence 
microscopy Olympus IX-71. Scale bar = 200 µm. 
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Figure. 9. Scanning electron microscopy of collagen scaffolds along with various ECM proteins 
without (left panel) or with hESCs (right panel). The following scaffolds were presented:  Col I 
(A, B), Col I + LM (C, D), Col I + FN (E, F), Col I + VN (G, H), Col I + Mix (I, J).  Scale bar = 
2 µm. 
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Figure. 10. Enhancement of DE differentiation in 3D collagen-based ECM scaffolds. (A) 
Quantitative PCR analysis of hESCs-induced DE cells after 4 days of culture in 2D and 3D 
collagen gel along with ECM proteins LM, FN, and VN. Relative gene expression levels in DE 
cells cultured in 3D were normalized to DE cells in 2D culture and beta-actin was used as 
calibration gene. (B) Flow cytometric analysis of Sox17 in definitive endoderm derived from 
human embryonic stem (ES) cells. DE cells were stained with either PE Mouse IgG1, κ isotype 
control (filled histogram) or PE Mouse Anti-human Sox17 antibody (open histogram) at matched 
concentrations.   
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Figure. 11. Immunohistochemical staining of definitive endoderm markers, Sox17 and Foxa2 in 
hESCs-induced cells culture in 2D and 3D scffolds made of collagen I along with laminin, 
fibronectin, and vitronectin. The definitive endoderm cells were examined after 4 days of 
differentiation. The nuclei were conterstained with DAPI. Scale bar = 50 µm. 
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Figure. 12. Quantitative PCR analysis of ECM gene expression of hESCs-induced DE cells in 
2D and 3D culture.  hESCs were induced into DE cells for 4 days in 2D or 3D collagen gel along 
with various ECM proteins such as LM, FN, and VN. Relative gene expression levels in DE cells 
cultured in 3D scaffolds were normalized to DE cells in 2D and beta-actin was used as 
calibration gene. 
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Figure. 13. Immunohistochemical staining of collagen IV secretion by DE differentiated cells in 
3D scaffolds made of various ECM proteins. After 4 days of DE differentiation, cells in 2D and 
3D culture were stained with rabbit anti-collagen IV primary antibody and TRITC conjugated 
donkey anti rabbit secondary antibody.  Nucleus was counterstained with DAPI. Scale bar=50 
μm. 
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Figure. 14. A modified step-wise protocol for differentiating human ES cells into insulin-
producing cells. Stage I: human ES cells were induced into definitive endoderm in the presence 
of activin A and wortmannin.  Stage II: the differentiated endoderm cells were treated with RA, 
KGF, Noggin and ILV to induce pancreatic progenitor formation. Stage III: cells were exposed 
to EGF to endorse pancreatic endoderm lineage specific differentiation. Stage IV: a cocktail of 
factors including nicotinamide, extendin-4, BMP4 and bFGF as utilized to promote the 
maturation of pancreatic β cells (this protocol is similar to Zhang, D. et al.’s approach but with 
some modification). 
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Figure. 15. Scanning electron micrographs of collagen I network incorporated with various 
concentration of Matrigel: (A, D) 10% Matrigel, (B, E), 35% Matrigel, (C, F) 50% Matrigel. 
Scale bars: A-C, 50 µm, D-F, 10 µm. 
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Figure. 16. Effect of Matrigel concentration in 3D collagen-I based scaffold on hESCs 
differentiation into definitive endoderm. (A) Quantitative PCR analysis of definitive endoderm 
markers of hESCs-derived DE cells after 4 days of differentiation  in 2D and 3D collagen gel 
along with 10%, 35%, 50% Matrigel. Expression level were normalized to β-actin. For each 
sample, relative expression levels were normalized to corresponding levels in cells under 2D 
culture. (B) Intracellular flow cytometric analysis of Sox17 at day 4 of DE differentiation in 2D 
and 3D collagen gel along with 10%, 35%, 50% Matrigel. DE cells were stained with either PE 
Mouse IgG1, κ isotype control (filled histogram) or PE Mouse Anti-human Sox17 antibody 
(open histogram) at matched concentrations.   
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Figure. 17. The morphology and viability of hESCs during pancreatic differentiation process in 
3D collagen/Matrigel scaffolds. (A-D) Phase contrast microscopy images of hESCs pancreatic 
differentiation at day 4 (A, C) and day 10 (B, D) in 2D (A, B) and collagen/Matrigel scaffold (C, 
D). (E-F) Live/dead staining of hESCs-differenting cells in collagen/Matrigel scaffold on day 4 
(E) and day 10 (F). 
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Figure. 18. The effect of (-)-indolactam V (ILV) on the differentiation of pancreatic progenitor 
from DE. (A) Immunofluorescence analysis of coexpression of PDX1 and HNF6 in hESCs-
induced pancreatic progenitor cells treated with or without ILV in 2D and 3D collagen/Matrigel. 
(B) Quantitative PCR analysis of pancreatic progenitor marker genes in hESCs-induced cells 
treated without or with ILV on day 5 and day8. Expression level were normalized to β-actin. All 
values are normalized to cells cultured on day 5 without ILV treatment.  
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Figure. 19. Double immunofluorescence analysis of pancreatic cells differentiated from hESCs. 
(A-C) PDX1 (A); NKX6.1 (B); merged images of PDX1, NKX6.1 and DAPI (C). (D-F) PDX1 
(D); NGN3 (E); merged images of PDX1, NGN3 and DAPI (F). (G-I) Insulin (G); C-peptide (H); 
merged images of insulin, C-peptide and DAPI. (J-L) Insulin (J); Somatostatin (K); merged 
images of insulin, somatostatin and DAPI. (M-O) Insulin (M); polypeptide (N); merged images 
of Insulin, polypeptide and DAPI. (P-R) Insulin (P); glucagon (Q); merged images of insulin, 
glucagon and DAPI (R). 
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Figure. 20. Quantitative PCR analysis showed the dynamic expression of several key genes 
during hESCs-induced pancreatic β cell development. Cell samples were collected at the end of 
stage I, stage II, stage III, and stage IV. mRNA of hESCs-induced cells at stage I in 2D culture 
was used as control to normalize gene expression level. β-actin was used as house-keeping gene. 
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Figure. 21. Insulin secretion in 2D and 3D culture. (A)  ELISA of glucose-response insulin 
release from 2D- and 3D- induced pancreatic cells exposed to 5.5 mM, 15 mM, and 25 mM 
glucose. (B) Flow cytometric analysis was performed using anti-human insulin antibodies with 
hESCs-induced pancreatic cells at the end of stage IV in 2D and 3D collagen/Matrigel scaffold. 
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Figure. 22. Transmission electron microscopic examinzation of insulin secretory granules in 
hESCs-differentiated pancreatic cells seed in 2D (A) and collagen/Matrigel scaffold (B). Scale 
bar = 2µm. 
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